69655-05-6 | 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one

Packsize	Purity	Availability	Price	Discounted Price
10mg	98%	in stock	$6.00	$4.00
50mg	98%	in stock	$8.00	$6.00
1g	98%	in stock	$42.00	$30.00
5g	98%	in stock	$106.00	$75.00
10g	98%	in stock	$179.00	$125.00
25g	98%	in stock	$323.00	$226.00
100g	98%	in stock	$713.00	$499.00

Description

• Catalog Number: AB48421
• Chemical Name: 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one
• CAS Number: 69655-05-6
• Molecular Formula: C10H12N4O3
• Molecular Weight: 236.2273
• MDL Number: MFCD00077728
• SMILES: OC[C@@H]1CC[C@@H](O1)n1cnc2c1[nH]cnc2=O

Computed Properties

• Complexity: 348
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 2
• Heavy Atom Count: 17
• Hydrogen Bond Acceptor Count: 5
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 2
• XLogP3: -1.2

Literature

• Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals.

  Chemical research in toxicology 20170515

• Design, synthesis, antimicrobial activity and anti-HIV activity evaluation of novel hybrid quinazoline-triazine derivatives.

  Journal of enzyme inhibition and medicinal chemistry 20140201

• Discovery of HIV-1 integrase inhibitors: pharmacophore mapping, virtual screening, molecular docking, synthesis, and biological evaluation.

  Chemical biology & drug design 20140201

• Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs.

  Bioorganic & medicinal chemistry 20140101

• Towards new C6-rigid S-DABO HIV-1 reverse transcriptase inhibitors: synthesis, biological investigation and molecular modeling studies.

  Bioorganic & medicinal chemistry 20131101

• Metabolic complications and treatment of perinatally HIV-infected children and adolescents.

  Journal of the International AIDS Society 20130101

• Synthesis of N₄ donor macrocyclic Schiff base ligands and their Ru (II), Pd (II), Pt (II) metal complexes for biological studies and catalytic oxidation of didanosine in pharmaceuticals.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20121101

• Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.

  AIDS research and human retroviruses 20121001

• Splenomegaly and variceal bleeding in a ten-year-old HIV-infected girl with noncirrhotic portal hypertension.

  The Pediatric infectious disease journal 20121001

• Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients.

  Journal of viral hepatitis 20121001

• Non-cirrhotic portal hypertension in HIV mono-infected patients.

  Journal of gastroenterology and hepatology 20120901

• Squalenoylation: a generic platform for nanoparticular drug delivery.

  Journal of controlled release : official journal of the Controlled Release Society 20120720

• Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity.

  AIDS (London, England) 20120717

• Molecular analysis of mitochondrial compromise in rodent cardiomyocytes exposed long term to nucleoside reverse transcriptase inhibitors (NRTIs).

  Cardiovascular toxicology 20120601

• Overall benefit of antiretroviral treatment on the risk of fracture in HIV: nested case-control analysis in a health-insured population.

  AIDS (London, England) 20120601

• Mitochondrial evolution in HIV-infected children receiving first- or second-generation nucleoside analogues.

  Journal of acquired immune deficiency syndromes (1999) 20120601

• p53 and mitochondrial DNA: their role in mitochondrial homeostasis and toxicity of antiretrovirals.

  The American journal of pathology 20120601

• The role of nucleoside reverse transcriptase inhibitors usage in the incidence of hyperlactatemia and lactic acidosis in HIV/AIDS patients.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20120601

• Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs.

  Toxicological sciences : an official journal of the Society of Toxicology 20120501

• Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.

  PLoS medicine 20120501

• Dipeptidyl peptidase IV (DPPIV/CD26)-based prodrugs of hydroxy-containing drugs.

  ChemMedChem 20120401

• Nanotechnology and the treatment of HIV infection.

  Viruses 20120401

• A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20120315

• Investigating the effect of Aloe vera gel on the buccal permeability of didanosine.

  Planta medica 20120301

• Exploring the complexity of the HIV-1 fitness landscape.

  PLoS genetics 20120301

• Pathogenesis and treatment of human immunodeficiency virus lipodystrophy.

  Indian journal of endocrinology and metabolism 20120301

• Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment.

  AIDS (London, England) 20120128

• The use of hot and cold high pressure homogenization to enhance the loading capacity and encapsulation efficiency of nanostructured lipid carriers for the hydrophilic antiretroviral drug, didanosine for potential administration to paediatric patients.

  Pharmaceutical development and technology 20120101

• Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.

  International journal of vascular medicine 20120101

• Reverse transcriptase genotypes in pediatric patients failing initial antiretroviral therapy in Gaborone, Botswana.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20120101

• Tuberculosis in pregnancy: a review.

  Journal of pregnancy 20120101

• E17A mutation in HIV-1 Vpr confers resistance to didanosine in association with thymidine analog mutations.

  Antiviral research 20120101

• Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery.

  Journal of drug delivery 20120101

• Intraepithelial γδ T cells remain increased in the duodenum of AIDS patients despite antiretroviral treatment.

  PloS one 20120101

• Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.

  BMC infectious diseases 20120101

• HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART.

  Advances in hematology 20120101

• Erythrocyte inosine triphosphatase activity is decreased in HIV-seropositive individuals.

  PloS one 20120101

• Noncirrhotic portal hypertension associated with didanosine: a case report and literature review.

  Japanese journal of infectious diseases 20120101

• HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selection.

  PLoS computational biology 20120101

• Common inherited mitochondrial DNA mutations and nucleoside reverse transcriptase inhibitor-induced severe hyperlactataemia in HIV-infected adults: an exploratory study.

  Antiviral therapy 20120101

• Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis.

  BMC health services research 20120101

• Aptamers in virology: recent advances and challenges.

  Frontiers in microbiology 20120101

• Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings.

  HIV/AIDS (Auckland, N.Z.) 20120101

• The combined use of known antiviral reverse transcriptase inhibitors AZT and DDI induce anticancer effects at low concentrations.

  Neoplasia (New York, N.Y.) 20120101

• Conference highlights of the 5th international workshop on HIV persistence during therapy, 6-9 December 2011, St. Maartin, West Indies.

  AIDS research and therapy 20120101

• Survival from XDR-TB is associated with modifiable clinical characteristics in rural South Africa.

  PloS one 20120101

• Antiretroviral nucleoside analogues suppress antibody synthesis in human B-lymphocytes.

  Antiviral therapy 20120101

• Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa.

  PloS one 20120101

• Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers.

  BMC gastroenterology 20120101

• HIV RNA suppression and immune restoration: can we do better?

  Clinical & developmental immunology 20120101

• HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone.

  PloS one 20120101

• HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.

  International journal of hepatology 20120101

• Plasma drug level validates self-reported adherence but predicts limited specificity for nonadherence to antiretroviral therapy.

  ISRN pharmacology 20120101

• Impact of Novel Resistance Profiles in HIV-1 Reverse Transcriptase on Phenotypic Resistance to NVP.

  AIDS research and treatment 20120101

• Challenges in Providing Treatment and Care for Viral Hepatitis among Individuals Co-Infected with HIV in Resource-Limited Settings.

  AIDS research and treatment 20120101

• Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial Data.

  AIDS research and treatment 20120101

• Failure to Control Caries in an AIDS-Affected Individual: A Case Report.

  Case reports in dentistry 20120101

• New option for management of HIV-1 infection in treatment-naive patients: once-daily, fixed-dose combination of rilpivirine-emtricitabine-tenofovir.

  HIV/AIDS (Auckland, N.Z.) 20120101

• Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma.

  Advances in hematology 20120101

• Influence of Age and Neurotoxic HAART Use on Frequency of HIV Sensory Neuropathy.

  AIDS research and treatment 20120101

• Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients.

  PloS one 20120101

• A pharmacovigilance study of adults on highly active antiretroviral therapy, South Africa: 2007 - 2011.

  The Pan African medical journal 20120101

• Fatal cumulative toxicities of HAART in a stable, AIDS-free, HIV-infected patient.

  BMJ case reports 20120101

• K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing data.

  PloS one 20120101

• Pharmacotherapy for multidrug resistant tuberculosis.

  Journal of pharmacology & pharmacotherapeutics 20120101

• Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence.

  PloS one 20120101

• Human immunodeficiency virus and leprosy coinfection: challenges in resource-limited setups.

  Case reports in medicine 20120101

• Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.

  International journal of nanomedicine 20120101

• Pan-pathway based interaction profiling of FDA-approved nucleoside and nucleobase analogs with enzymes of the human nucleotide metabolism.

  PloS one 20120101

• Second-line antiretroviral therapy in a workplace and community-based treatment programme in South Africa: determinants of virological outcome.

  PloS one 20120101

• Antiretroviral drugs: critical issues and recent advances.

  Indian journal of pharmacology 20120101

• VS411 reduced immune activation and HIV-1 RNA levels in 28 days: randomized proof-of-concept study for antiviral-hyperactivation limiting therapeutics.

  PloS one 20120101

• Selection and characterization of suitable lipid excipients for use in the manufacture of didanosine-loaded solid lipid nanoparticles and nanostructured lipid carriers.

  Journal of pharmaceutical sciences 20111201

• Herpes zoster as a sign of AIDS and nonadherence to antiretroviral therapy: a case report.

  Clinics (Sao Paulo, Brazil) 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• [Regenerative nodular hyperplasia in HIV].

  Acta gastroenterologica Latinoamericana 20111201

• Antiretroviral therapy in Indian setting: when & what to start with, when & what to switch to?

  The Indian journal of medical research 20111201

• Human immunodeficiency virus & cardiovascular risk.

  The Indian journal of medical research 20111201

• How much do antiretroviral drugs penetrate into the central nervous system?

  Journal of medicine and life 20111114

• Hyperlactataemia in HIV-infected subjects initiating antiretroviral therapy in a large randomized study (a substudy of the INITIO trial).

  HIV medicine 20111101

• Genotypic resistance at viral rebound among patients who received lopinavir/ritonavir-based or efavirenz-based first antiretroviral therapy in South Africa.

  Journal of acquired immune deficiency syndromes (1999) 20111101

• High prevalence of distal sensory polyneuropathy in antiretroviral-treated and untreated people with HIV in Tanzania.

  Tropical medicine & international health : TM & IH 20111001

• Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20111001

• Impact of lamivudine on HIV and hepatitis B virus-related outcomes in HIV/hepatitis B virus individuals in a randomized clinical trial of antiretroviral therapy in southern Africa.

  AIDS (London, England) 20110910

• Evaluation of the in vitro differential protein adsorption patterns of didanosine-loaded nanostructured lipid carriers (NLCs) for potential targeting to the brain.

  Journal of liposome research 20110901

• Mother-to-fetus transfer of antiviral drugs and the involvement of transporters at the placental barrier.

  Journal of pharmaceutical sciences 20110901

• Treatment switches during pregnancy among HIV-positive women on antiretroviral therapy at conception.

  AIDS (London, England) 20110824

• The base component of 3'-azido-2',3'-dideoxynucleosides influences resistance mutations selected in HIV-1 reverse transcriptase.

  Antimicrobial agents and chemotherapy 20110801

• Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries.

  Journal of acquired immune deficiency syndromes (1999) 20110801

• Prevalence of antiretroviral drug resistance mutations and HIV-I subtypes among newly-diagnosed drug-naïve persons visiting a voluntary testing and counselling centre in northeastern South Africa.

  Journal of health, population, and nutrition 20110801

• A new nanomedicine based on didanosine glycerolipidic prodrug enhances the long term accumulation of drug in a HIV sanctuary.

  International journal of pharmaceutics 20110729

• Impact of HAART exposure and associated lipodystrophy on advanced liver fibrosis in HIV/HCV-coinfected patients.

  Journal of viral hepatitis 20110701

• Short-term virological efficacy, immune reconstitution, tolerance, and adherence of once-daily dosing of didanosine, lamivudine, and efavirenz in HIV-1-infected African children: ANRS 12103 Burkiname.

  Journal of acquired immune deficiency syndromes (1999) 20110701

• [The prevalence of HIV-1 drug resistance and associated factors in AIDS patients receiving HAART in Zhecheng county, Henan province].

  Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] 20110701

• [Protective role of antiretroviral treatment in the impairment of renal function in a cohort of human immunodeficiency virus patients].

  Medicina clinica 20110625

• [Occurrence of human immunodeficiency virus-1 resistance through a six-year surveillance in rural areas of Henan].

  Zhonghua yi xue za zhi 20110607

• Combination anti-HIV therapy with the self-assemblies of an asymmetric bolaamphiphilic zidovudine/didanosine prodrug.

  Molecular pharmaceutics 20110606

• The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro.

  Antimicrobial agents and chemotherapy 20110601

• Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters.

  Laboratory investigation; a journal of technical methods and pathology 20110601

• Pharmacology and immuno-virologic efficacy of once-a-day HAART in African HIV-infected children: ANRS 12103 phase II trial.

  Bulletin of the World Health Organization 20110601

• Non-cirrhotic portal hypertension in HIV-infected individuals.

  International journal of STD & AIDS 20110601

• Major HIV resistance mutations in untreated Romanian patients.

  Journal of medicine and life 20110515

• Molecular recognition of the antiretroviral drug abacavir: towards the development of a novel carbazole-based fluorosensor.

  Journal of fluorescence 20110501

• [Characteristics of antiretroviral drugs].

  Enfermedades infecciosas y microbiologia clinica 20110501

• Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.

  Molecular pharmaceutics 20110404

• Cohort profile: Hlabisa HIV treatment and care programme.

  International journal of epidemiology 20110401

• Formulation development and in vitro evaluation of didanosine-loaded nanostructured lipid carriers for the potential treatment of AIDS dementia complex.

  Drug development and industrial pharmacy 20110401

• Relationship between neck circumference and cardiometabolic parameters in HIV-infected and non-HIV-infected adults.

  Diabetes care 20110401

• Antiviral hyperactivation-limiting therapeutics as a novel class for the treatment of HIV/AIDS: focus on VS411.

  Expert opinion on investigational drugs 20110401

• Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists.

  Pharmacotherapy 20110401

• Predictors for the emergence of the 2 multi-nucleoside/nucleotide resistance mutations 69 insertion and Q151M and their impact on clinical outcome in the Swiss HIV cohort study.

  The Journal of infectious diseases 20110315

• The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia in HIV-infected patients: a case control study.

  Journal of hepatology 20110301

• In vitro assessment of the adverse effects of antiretroviral drugs on the human male gamete.

  Toxicology in vitro : an international journal published in association with BIBRA 20110301

• HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.

  Current HIV/AIDS reports 20110301

• Type 2 diabetes and impaired glucose tolerance in two young adults infected with HIV early in life.

  Diabetes care 20110301

• Quantification of the relative importance of CTL, B cell, NK cell, and target cell limitation in the control of primary SIV-infection.

  PLoS computational biology 20110301

• Dyslipidemia among HIV-infected Patients with tuberculosis taking once-daily nonnucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in India.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110215

• The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV.

  Virchows Archiv : an international journal of pathology 20110201

• Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.

  Tropical medicine & international health : TM & IH 20110201

• Noncirrhotic portal hypertension in HIV infection.

  Current opinion in infectious diseases 20110201

• Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.

  The Journal of antimicrobial chemotherapy 20110201

• Additive effects of numbness and muscle aches on fatigue occurrence in individuals with HIV/AIDS who are taking antiretroviral therapy.

  Journal of pain and symptom management 20110201

• Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.

  AIDS (London, England) 20110114

• Lipoatrophy of the footpad in HIV-treated patients is associated with increased PAI-1.

  Biological research for nursing 20110101

• Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance.

  Journal of viral hepatitis 20110101

• Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure.

  HIV medicine 20110101

• Hodgkin's Disease in Patients with HIV Infection.

  Advances in hematology 20110101

• Determination of the antiretroviral drug nevirapine in diluted alkaline electrolyte by adsorptive stripping voltammetry at the mercury film electrode.

  Combinatorial chemistry & high throughput screening 20110101

• Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial).

  The Journal of antimicrobial chemotherapy 20110101

• Noncirrhotic portal hypertension and didanosine: a re-analysis.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20110101

• Understanding diabetes in patients with HIV/AIDS.

  Diabetology & metabolic syndrome 20110101

• Timing of antiretroviral therapy for HIV in the setting of TB treatment.

  Clinical & developmental immunology 20110101

• Expenditures for the care of HIV-infected patients in rural areas in China's antiretroviral therapy programs.

  BMC medicine 20110101

• K70Q adds high-level tenofovir resistance to 'Q151M complex' HIV reverse transcriptase through the enhanced discrimination mechanism.

  PloS one 20110101

• A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus.

  Virology journal 20110101

• Clinical monitoring and correlates of nephropathy in SIV-infected macaques during high-dose antiretroviral therapy.

  AIDS research and therapy 20110101

• Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine.

  PloS one 20110101

• Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI.

  BMC infectious diseases 20110101

• Clinical significance of HIV-1 coreceptor usage.

  Journal of translational medicine 20110101

• Human immunodeficiency virus type 2 in two Saudi families.

  Annals of Saudi medicine 20110101

• A biregional survey and review of first-line treatment failure and second-line paediatric antiretroviral access and use in Asia and southern Africa.

  Journal of the International AIDS Society 20110101

• Management of HIV-1 associated hepatitis in patients with acquired immunodeficiency syndrome: role of a successful control of viral replication.

  AIDS research and therapy 20110101

• Timely HAART initiation may pave the way for a better viral control.

  BMC infectious diseases 20110101

• Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort.

  PloS one 20110101

• Correcting for mortality among patients lost to follow up on antiretroviral therapy in South Africa: a cohort analysis.

  PloS one 20110101

• 'Dynamic range' of inferred phenotypic HIV drug resistance values in clinical practice.

  PloS one 20110101

• Highly active antiretroviral therapy: Does it Sound toxic?

  Journal of pharmacy & bioallied sciences 20110101

• High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia.

  Journal of the International AIDS Society 20110101

• Machine learning on normalized protein sequences.

  BMC research notes 20110101

• Lysosomotropic agents as HCV entry inhibitors.

  Virology journal 20110101

• Tinea incognito Caused by Microsporum gypseum in a Patient with Advanced HIV Infection: A Case Report.

  Case reports in dermatology 20110101

• Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource Settings.

  AIDS research and treatment 20110101

• Protease Inhibitor Resistance Is Uncommon in HIV-1 Subtype C Infected Patients on Failing Second-Line Lopinavir/r-Containing Antiretroviral Therapy in South Africa.

  AIDS research and treatment 20110101

• CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy.

  AIDS research and treatment 20110101

• A risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapy.

  PloS one 20110101

• Improved antiretroviral treatment outcome in a rural African setting is associated with cART initiation at higher CD4 cell counts and better general health condition.

  BMC infectious diseases 20110101

• Effect of reverse transcriptase inhibitors on LINE-1 and Ty1 reverse transcriptase activities and on LINE-1 retrotransposition.

  BMC biochemistry 20110101

• Factors influencing retention in care after starting antiretroviral therapy in a rural South African programme.

  PloS one 20110101

• Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda.

  PloS one 20110101

• The evolution of HIV-1 reverse transcriptase in route to acquisition of Q151M multi-drug resistance is complex and involves mutations in multiple domains.

  Retrovirology 20110101

• The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data.

  Journal of the International AIDS Society 20110101

• Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects.

  PloS one 20110101

• Safety and tolerability of antiretrovirals during pregnancy.

  Infectious diseases in obstetrics and gynecology 20110101

• Presentation and outcome of tuberculous meningitis in a high HIV prevalence setting.

  PloS one 20110101

• Outcome assessment of a dedicated HIV positive health care worker clinic at a central hospital in Malawi: a retrospective observational study.

  PloS one 20110101

• Contraception in HIV-positive female adolescents.

  AIDS research and therapy 20110101

• Conformational alterations in the CD4 binding cavity of HIV-1 gp120 influencing gp120-CD4 interactions and fusogenicity of HIV-1 envelopes derived from brain and other tissues.

  Retrovirology 20110101

• Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons: implications for HIV-associated neurocognitive disorders.

  Molecular brain 20110101

• Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis.

  PloS one 20110101

• Decreased heart rate variability in HIV positive patients receiving antiretroviral therapy: importance of blood glucose and cholesterol.

  PloS one 20110101

• Increased sensitivity to broadly neutralizing antibodies of end-stage disease R5 HIV-1 correlates with evolution in Env glycosylation and charge.

  PloS one 20110101

• Tenofovir nephrotoxicity: 2011 update.

  AIDS research and treatment 20110101

• Virological breakthrough: a risk factor for loss to followup in a large community-based cohort on antiretroviral therapy.

  AIDS research and treatment 20110101

• Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy.

  PloS one 20110101

• Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure.

  PloS one 20110101

• Reappearance of minority K103N HIV-1 variants after interruption of ART initiated during primary HIV-1 infection.

  PloS one 20110101

• Non-cirrhotic portal hypertension in human immunodeficiency virus-infected patients: a new challenge in antiretroviral therapy era.

  The open AIDS journal 20110101

• BK Virus in Kidney Transplant Recipients: The Influence of Immunosuppression.

  Journal of transplantation 20110101

• Synthesis and Biological Evaluation of New 3-Phenyl-1-[(4-arylpiperazin-1-yl)alkyl]-piperidine-2,6-diones.

  Scientia pharmaceutica 20110101

• Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda.

  BMC pediatrics 20110101

• Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs.

  Patient preference and adherence 20110101

• Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?

  PloS one 20110101

• Nephrotoxicity of HAART.

  AIDS research and treatment 20110101

• Acute pancreatitis with saw palmetto use: a case report.

  Journal of medical case reports 20110101

• HIV drug resistance (HIVDR) in antiretroviral therapy-naïve patients in Tanzania not eligible for WHO threshold HIVDR survey is dramatically high.

  PloS one 20110101

• Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 PI-based regimen.

  PloS one 20110101

• Early outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa.

  Antiviral therapy 20110101

• The value of screening HIV-infected individuals for didanosine-related liver disease?

  Antiviral therapy 20110101

• Government use licenses in Thailand: The power of evidence, civil movement and political leadership.

  Globalization and health 20110101

• Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.

  BMC infectious diseases 20110101

• A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries.

  Globalization and health 20110101

• Immunological failure despite virological suppression in HIV seropositive individuals on antiretroviral therapy.

  Indian journal of sexually transmitted diseases and AIDS 20110101

• South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.

  Indian journal of endocrinology and metabolism 20110101

• Human immunodeficiency virus endocrinopathy.

  Indian journal of endocrinology and metabolism 20110101

• Increase of transmitted drug resistance among HIV-infected sub-Saharan Africans residing in Spain in contrast to the native population.

  PloS one 20110101

• Factors associated with paradoxical immune response to antiretroviral therapy in HIV infected patients: a case control study.

  BMC infectious diseases 20110101

• A prospective study of vaginal trichomoniasis and HIV-1 shedding in women on antiretroviral therapy.

  BMC infectious diseases 20110101

• Male gender predicts mortality in a large cohort of patients receiving antiretroviral therapy in Uganda.

  Journal of the International AIDS Society 20110101

• Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy.

  BMC infectious diseases 20110101

• Complete Healing of a Giant Wart in a Severely Immune-Compromised Patient with HIV Infection Treated with Acupuncture.

  Case reports in dermatology 20110101

• Nevirapine plasma concentrations are associated with virologic response and hepatotoxicity in Chinese patients with HIV infection.

  PloS one 20110101

• Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomised trial.

  BMJ (Clinical research ed.) 20110101

• CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study.

  BMJ (Clinical research ed.) 20110101

• Effect of anemia on hepatotoxicity of HAART in HIV patients in Benin city.

  Nigerian medical journal : journal of the Nigeria Medical Association 20110101

• It is time to consider third-line options in antiretroviral-experienced paediatric patients?

  Journal of the International AIDS Society 20110101

• Impact of comorbidities and drug therapy on development of renal impairment in a predominantly African American and Hispanic HIV clinic population.

  HIV/AIDS (Auckland, N.Z.) 20110101

• Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study.

  BMJ (Clinical research ed.) 20110101

• Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score.

  PloS one 20110101

• AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus.

  BMC research notes 20110101

• Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

  PloS one 20110101

• Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells.

  Antiviral therapy 20110101

• Intensification of antiretroviral therapy with a CCR5 antagonist in patients with chronic HIV-1 infection: effect on T cells latently infected.

  PloS one 20110101

• Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection.

  PloS one 20110101

• Nanomedicine as an emerging approach against intracellular pathogens.

  International journal of nanomedicine 20110101

• Enhanced immunomodulatory activity of gelatin-encapsulated Rubus coreanus Miquel nanoparticles.

  International journal of molecular sciences 20110101

• Formulation and evaluation of a sustained-release tablets of metformin hydrochloride using hydrophilic synthetic and hydrophobic natural polymers.

  Indian journal of pharmaceutical sciences 20110101

• Nodular regenerative hyperplasia of the liver associated with didanosine persists for years even after its interruption.

  BMJ case reports 20110101

• Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20101215

• Chemoenzymatic syntheses and anti-HIV-1 activity of glucose-nucleoside conjugates as prodrugs.

  Bioconjugate chemistry 20101215

• Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages.

  The Journal of biological chemistry 20101210

• MRN-100, an Iron-based Compound, Possesses Anti-HIV Activity In Vitro.

  Evidence-based complementary and alternative medicine : eCAM 20101201

• Changing baseline characteristics among patients in the China National Free Antiretroviral Treatment Program, 2002-09.

  International journal of epidemiology 20101201

• Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.

  Viruses 20101201

• A case of oesophageal varices and portal hypertension in an HIV-positive patient with no evidence of cirrhosis.

  The New Zealand medical journal 20101126

• A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 cells/μL in South Africa.

  The Journal of infectious diseases 20101115

• Progressive mitochondrial compromise in brains and livers of primates exposed in utero to nucleoside reverse transcriptase inhibitors (NRTIs).

  Toxicological sciences : an official journal of the Society of Toxicology 20101101

• Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

  Archives of toxicology 20101101

• Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.

  Viruses 20101101

• Nano-NRTIs: efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity.

  Antiviral chemistry & chemotherapy 20101028

• Semiparametric analysis of recurrent events: artificial censoring, truncation, pairwise estimation and inference.

  Lifetime data analysis 20101001

• Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of resensitising mutations including K65R.

  The Journal of infection 20101001

• Strategies to improve efficacy and safety of a novel class of antiviral hyper-activation-limiting therapeutic agents: the VS411 model in [corrected] HIV/AIDS.

  British journal of pharmacology 20101001

• Bristol-Myers Squibb clarification on didanosine supply.

  Lancet (London, England) 20100925

• Genotypic and phenotypic cross-drug resistance of harboring drug-resistant HIV type 1 subtype B' strains from former blood donors in central Chinese provinces.

  AIDS research and human retroviruses 20100901

• Design and directed evolution of a dideoxy purine nucleoside phosphorylase.

  Protein engineering, design & selection : PEDS 20100801

• Methadone, buprenorphine, and street drug interactions with antiretroviral medications.

  Current HIV/AIDS reports 20100801

• Using touchscreen electronic medical record systems to support and monitor national scale-up of antiretroviral therapy in Malawi.

  PLoS medicine 20100801

• Is there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report.

  Viruses 20100801

• Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.

  Antimicrobial agents and chemotherapy 20100701

• Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20100701

• New trends in nucleoside biotechnology.

  Acta naturae 20100701

• A weighted combination of pseudo-likelihood estimators for longitudinal binary data subject to non-ignorable non-monotone missingness.

  Statistics in medicine 20100630

• Open letter to Lamberto Andreotti, Chief Executive Officer, Bristol-Myers Squibb.

  Lancet (London, England) 20100626

• Successful paediatric HIV treatment in rural primary care in Africa.

  Archives of disease in childhood 20100601

• Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting; an attractive route against infections caused by AIDS viruses.

  Journal of drug targeting 20100601

• Risk factors in human immunodeficiency virus/acquired immunodeficiency syndrome patients undergoing antiretroviral therapy in the state of Pernambuco, Brazil: a case-control study.

  Metabolic syndrome and related disorders 20100601

• Abacavir and didanosine induce the interaction between human leukocytes and endothelial cells through Mac-1 upregulation.

  AIDS (London, England) 20100601

• Albumin uptake in OK cells exposed to rotenone: a model for studying the effects of mitochondrial dysfunction on endocytosis in the proximal tubule?

  Nephron. Physiology 20100601

• Nucleoside phosphorylases from clostridium perfringens in the synthesis of 2',3'-dideoxyinosine.

  Nucleosides, nucleotides & nucleic acids 20100601

• Noncirrhotic portal hypertension in HIV-infected patients: unique clinical and pathological findings.

  AIDS (London, England) 20100515

• Long-term AZT exposure alters the metabolic capacity of cultured human lymphoblastoid cells.

  Toxicological sciences : an official journal of the Society of Toxicology 20100501

• Efficacy and safety of unboosted atazanavir in combination with lamivudine and didanosine in naive HIV type 1 patients in Senegal.

  AIDS research and human retroviruses 20100501

• Recent FDA approvals and changes.

  AIDS patient care and STDs 20100501

• Breast enlargement in an HIV-infected man on combined antiretroviral therapy: what if it was carcinoma?

  International journal of STD & AIDS 20100501

• Perturbation of the developmental potential of preimplantation mouse embryos by hydroxyurea.

  International journal of environmental research and public health 20100501

• Didanosine polymorphism in a supercritical antisolvent process.

  Journal of pharmaceutical sciences 20100401

• High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa.

  Journal of acquired immune deficiency syndromes (1999) 20100401

• Ubisol-Aqua: coenzyme Q10 prevents antiretroviral toxic neuropathy in an in vitro model.

  Current HIV research 20100401

• Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine.

  The Journal of antimicrobial chemotherapy 20100401

• A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants.

  PLoS computational biology 20100401

• FDA notifications. Rare complication with didanosine.

  AIDS alert 20100401

• Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100315

• Another milestone in minimizing risks to mothers exposed to single-dose nevirapine for prevention of vertical transmission of HIV-1 to infants: what next?

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100315

• [Evolution of HIV-1 drug resistance in patients failing combination antiretroviral therapy].

  Zhonghua yi xue za zhi 20100309

• Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa.

  Cancer causes & control : CCC 20100301

• The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study.

  Journal of acquired immune deficiency syndromes (1999) 20100301

• Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients.

  International journal of STD & AIDS 20100301

• Timing of initiation of antiretroviral drugs during tuberculosis therapy.

  The New England journal of medicine 20100225

• Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.

  The Journal of antimicrobial chemotherapy 20100201

• Simultaneous determination of didanosine and its amino acid prodrug, valdidanosine by hydrophilic interaction chromatography coupled with electrospray ionization tandem mass spectrometry: application to a pharmacokinetic study in rats.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20100201

• Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

  The Journal of infectious diseases 20100201

• Imatinib-induced pancreatitis.

  Indian journal of pharmacology 20100201

• Melanonychia and skin hyperpigmentation with hydroxyurea therapy.

  Indian journal of pharmacology 20100201

• HIV Genetic Diversity and Drug Resistance.

  Viruses 20100201

• Risk factors, management and outcomes of adverse drug reactions in adult patients on antiretrovirals at Kenyatta National Hospital, Nairobi.

  East African medical journal 20100201

• Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets.

  AIDS (London, England) 20100128

• Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20100115

• Modelling imperfect adherence to HIV induction therapy.

  BMC infectious diseases 20100101

• Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient.

  BMC gastroenterology 20100101

• Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.

  The American journal on addictions 20100101

• Patent Pooling for Promoting Access to Antiretroviral Drugs (ARVs) - A Strategic Option for India.

  The open AIDS journal 20100101

• Expression and functional activity of nucleoside transporters in human choroid plexus.

  Cerebrospinal fluid research 20100101

• Cerebral FDG-PET scanning abnormalities in optimally treated HIV patients.

  Journal of neuroinflammation 20100101

• HIV-induced immune activation: pathogenesis and clinical relevance - summary of a workshop organized by the German AIDS Society (DAIG e.v.) and the ICH Hamburg, Hamburg, Germany, November 22, 2008.

  European journal of medical research 20100101

• Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.

  Antiviral therapy 20100101

• Profile of etravirine for the treatment of HIV infection.

  Therapeutics and clinical risk management 20100101

• Technology Development Through Pooling ARV Drug Patents: A Vision from China.

  The open AIDS journal 20100101

• Abacavir/lamivudine combination in the treatment of HIV: a review.

  Therapeutics and clinical risk management 20100101

• Efficacy, safety and pharmacokinetic of once-daily boosted saquinavir (1500/100 mg) together with 2 nucleos(t)ide reverse transcriptase inhibitors in real life: a multicentre prospective study.

  AIDS research and therapy 20100101

• High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia.

  Journal of the International AIDS Society 20100101

• Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.

  PloS one 20100101

• The Development and Implementation of an Outreach Program to Identify Acute and Recent HIV Infections in New York City.

  The open AIDS journal 20100101

• Markers of inflammation and coagulation indicate a prothrombotic state in HIV-infected patients with long-term use of antiretroviral therapy with or without abacavir.

  AIDS research and therapy 20100101

• Pharmacokinetic characterization of three doses of tipranavir boosted with ritonavir on highly active antiretroviral therapy in treatment-experienced HIV-1 patients.

  HIV clinical trials 20100101

• The cost-effectiveness of directly observed highly-active antiretroviral therapy in the third trimester in HIV-infected pregnant women.

  PloS one 20100101

• Increasing rates of obesity among HIV-infected persons during the HIV epidemic.

  PloS one 20100101

• 'I will not let my HIV status stand in the way.' Decisions on motherhood among women on ART in a slum in Kenya- a qualitative study.

  BMC women's health 20100101

• A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda.

  PloS one 20100101

• Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity.

  European journal of medical research 20100101

• HAART and the liver: friend or foe?

  European journal of medical research 20100101

• The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive Individuals.

  European journal of medical research 20100101

• [Non-cirrhotic portal hypertension: rare cause of upper gastrointestinal bleeding].

  Nederlands tijdschrift voor geneeskunde 20100101

• Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients.

  BMC infectious diseases 20100101

• Semen may harbor HIV despite effective HAART: another piece in the puzzle.

  PloS one 20100101

• Recent key advances in human immunodeficiency virus medicine and implications for China.

  AIDS research and therapy 20100101

• Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.

  Antiviral therapy 20100101

• Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America.

  PloS one 20100101

• Nucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutation.

  PloS one 20100101

• Rapid improvement in fasting lipids and hepatic toxicity after switching from didanosine/lamivudine to tenofovir/emtricitabine in patients with toxicity attributable to didanosine.

  HIV clinical trials 20100101

• Risk of myocardial infarction in parents of HIV-infected Individuals: a population-based Cohort Study.

  BMC infectious diseases 20100101

• Generic and low dose antiretroviral therapy in adults and children: implication for scaling up treatment in resource limited settings.

  AIDS research and therapy 20100101

• Financing equitable access to antiretroviral treatment in South Africa.

  BMC health services research 20100101

• Development of a liposomal nanodelivery system for nevirapine.

  Journal of biomedical science 20100101

• Dynamics of HIV-1 quasispecies during antiviral treatment dissected using ultra-deep pyrosequencing.

  PloS one 20100101

• The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants.

  PloS one 20100101

• Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children.

  Journal of the International AIDS Society 20100101

• Evaluation of HIV protease and nucleoside reverse transcriptase inhibitors on proliferation, necrosis, apoptosis in intestinal epithelial cells and electrolyte and water transport and epithelial barrier function in mice.

  BMC gastroenterology 20100101

• Prevalence and risk factors for abnormal liver stiffness in HIV-infected patients without viral hepatitis coinfection: role of didanosine.

  Antiviral therapy 20100101

• Inhibition of allogeneic inflammatory responses by the Ribonucleotide Reductase Inhibitors, Didox and Trimidox.

  Journal of inflammation (London, England) 20100101

• Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors.

  Retrovirology 20100101

• Association between HIV replication and serum leptin levels: an observational study of a cohort of HIV-1-infected South African women.

  Journal of the International AIDS Society 20100101

• Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection.

  Retrovirology 20100101

• Assessing the performance of a computer-based policy model of HIV and AIDS.

  PloS one 20100101

• Knowledge and adherence to antiretroviral therapy among adult people living with HIV/AIDS treated in the health care centers of the association 'Espoir Vie Togo' in Togo, West Africa.

  BMC clinical pharmacology 20100101

• Antibiotic optimization in the difficult-to-treat patient with complicated intra-abdominal or complicated skin and skin structure infections: focus on tigecycline.

  Therapeutics and clinical risk management 20100101

• Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen.

  Clinical epidemiology 20100101

• Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens.

  AIDS research and therapy 20100101

• Patients present earlier and survival has improved, but pre-ART attrition is high in a six-year HIV cohort data from Ethiopia.

  PloS one 20100101

• The global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children.

  BMC pediatrics 20100101

• Progress in antiretroviral drug delivery using nanotechnology.

  International journal of nanomedicine 20100101

• Predictors of adherence to antiretroviral therapy among people living with HIV/AIDS in resource-limited setting of southwest ethiopia.

  AIDS research and therapy 20100101

• Long-term adherence to antiretroviral treatment and program drop-out in a high-risk urban setting in sub-Saharan Africa: a prospective cohort study.

  PloS one 20100101

• Immune reconstitution inflammatory syndrome presenting as chylothorax in a patient with HIV and Mycobacterium tuberculosis coinfection: a case report.

  BMC infectious diseases 20100101

• Antiretroviral therapy optimisation without genotype resistance testing: a perspective on treatment history based models.

  PloS one 20100101

• HIV-infected former plasma donors in rural Central China: from infection to survival outcomes, 1985-2008.

  PloS one 20100101

• Contraceptive use and method preference among women in Soweto, South Africa: the influence of expanding access to HIV care and treatment services.

  PloS one 20100101

• Uridine metabolism in HIV-1-infected patients: effect of infection, of antiretroviral therapy and of HIV-1/ART-associated lipodystrophy syndrome.

  PloS one 20100101

• Comparison of antiviral activity of regimens containing nucleos(t)ide (NUC) Pairs in HIV-Infected Patients Initiating REScue therapy (The NUCREST Study).

  HIV clinical trials 20100101

• Utility of quantitative sensory testing and screening tools in identifying HIV-associated peripheral neuropathy in Western Kenya: pilot testing.

  PloS one 20100101

• Proteochemometric modeling of the susceptibility of mutated variants of the HIV-1 virus to reverse transcriptase inhibitors.

  PloS one 20100101

• Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials.

  PloS one 20100101

• Pseudogout Associated Hip Pain in a Patient with HIV Infection.

  Case reports in medicine 20100101

• Postexposure prophylaxis for deadly bloodborne viral infections.

  Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer 20100101

• Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.

  Cholesterol 20100101

• Raltegravir in combination with other antiretroviral agents for the treatment of HIV infection.

  Infection and drug resistance 20100101

• The use of anti-tuberculosis therapy for latent TB infection.

  Infection and drug resistance 20100101

• Determination of site of absorption of propranolol in rat gut using in situ single-pass intestinal perfusion.

  Indian journal of pharmaceutical sciences 20100101

• Beyond the black box: drug- and device-associated hypersensitivity events.

  Drug, healthcare and patient safety 20100101

• HIV Infection, Antiretroviral Therapy and Cardiovascular Risk.

  Mediterranean journal of hematology and infectious diseases 20100101

• Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India.

  Indian journal of sexually transmitted diseases and AIDS 20100101

• Zidovudine-induced myopathy: A study in Indian patients.

  Journal of neurosciences in rural practice 20100101

• Optimal management of oropharyngeal and esophageal candidiasis in patients living with HIV infection.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Long-term treatment of patients with HIV-1: the role of atazanavir.

  HIV/AIDS (Auckland, N.Z.) 20100101

• Oral manifestations of HIV.

  Contemporary clinical dentistry 20100101

• Highly active antiretroviral therapy drugs inhibit in vitro cholesterol efflux from human macrophage-derived foam cells.

  Laboratory investigation; a journal of technical methods and pathology 20091201

• Risk of extended viral resistance in human immunodeficiency virus-1-infected Mozambican children after first-line treatment failure.

  The Pediatric infectious disease journal 20091201

• The hemostatic balance in HIV-infected patients with and without antiretroviral therapy: partial restoration with antiretroviral therapy.

  AIDS patient care and STDs 20091201

• Antiretroviral genotypic resistance mutations in HIV-1 infected Korean patients with virologic failure.

  Journal of Korean medical science 20091201

• Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis.

  PLoS medicine 20091201

• [Treatment of chronic hepatitis C in human immunodeficiency virus infected patients].

  Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti 20091201

• Efavirenz: a decade of clinical experience in the treatment of HIV.

  The Journal of antimicrobial chemotherapy 20091101

• Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.

  AIDS research and human retroviruses 20091101

• Didanosine ester prodrugs: synthesis, albumin binding properties and pharmacokinetic studies in rats.

  European journal of medicinal chemistry 20091001

• Prolonged chronic phase of greater than 10 years of chronic myelogenous leukemia in a patient with congenital human immunodefeciency virus infection.

  Pediatric blood & cancer 20091001

• Centrosome amplification induced by the antiretroviral nucleoside reverse transcriptase inhibitors lamivudine, stavudine, and didanosine.

  Environmental and molecular mutagenesis 20091001

• A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype.

  Journal of medical virology 20091001

• Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone.

  Clinical and experimental immunology 20091001

• A prospective, observational cohort study to elicit adverse effects of antiretroviral agents in a remote resource-restricted tribal population of Chhattisgarh.

  Indian journal of pharmacology 20091001

• Metabolism evaluation of biomimetic prodrugs by in vitro models and mass spectrometry.

  International journal of pharmaceutics 20090911

• CXCR3 activation by lentivirus infection suppresses neuronal autophagy: neuroprotective effects of antiretroviral therapy.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20090901

• The intestinal permeation of didanosine from granules containing microspheres using the everted gut sac model.

  Journal of microencapsulation 20090901

• The role of transporters in the pharmacokinetics of orally administered drugs.

  Pharmaceutical research 20090901

• Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.

  Antimicrobial agents and chemotherapy 20090901

• Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel.

  Journal of medical virology 20090901

• The history of antiretrovirals: key discoveries over the past 25 years.

  Reviews in medical virology 20090901

• [Cardiovascular risk factors associated with antiretroviral therapy].

  Enfermedades infecciosas y microbiologia clinica 20090901

• Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20090815

• Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus.

  Medical microbiology and immunology 20090801

• FDA notifications. New labeling for Videx pediatric powder.

  AIDS alert 20090801

• [Therapeutic effect and safety evaluation on 6-year highly active antiretroviral therapy for Chinese HIV-1 infected patients].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20090801

• Ophthalmoplegia and ptosis: mitochondrial toxicity in patients receiving HIV therapy.

  Neurology 20090707

• The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir.

  Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 20090701

• WR1065 mitigates AZT-ddI-induced mutagenesis and inhibits viral replication.

  Environmental and molecular mutagenesis 20090701

• The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20090701

• Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats.

  Journal of acquired immune deficiency syndromes (1999) 20090701

• Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome.

  PLoS computational biology 20090701

• Renal transplantation in a HIV positive patient.

  Indian journal of nephrology 20090701

• Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy.

  The Journal of infectious diseases 20090601

• Drug resistance in the Chinese National Pediatric Highly Active Antiretroviral Therapy Cohort: implications for paediatric treatment in the developing world.

  International journal of STD & AIDS 20090601

• Long-term suppressive therapy for pulmonary aspergilloma in an immunocompromised man with AIDS. Is it always necessary?

  International journal of STD & AIDS 20090601

• Assessment of mitochondrial toxicity by analysis of mitochondrial protein expression in mononuclear cells.

  Cytometry. Part B, Clinical cytometry 20090501

• The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.

  Antiviral research 20090501

• Tenofovir renal toxicity targets mitochondria of renal proximal tubules.

  Laboratory investigation; a journal of technical methods and pathology 20090501

• Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.

  Journal of acquired immune deficiency syndromes (1999) 20090501

• Oral complications of HIV disease.

  Clinics (Sao Paulo, Brazil) 20090501

• Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda.

  AIDS (London, England) 20090427

• Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies.

  Lancet (London, England) 20090418

• Screening and monitoring antiretrovirals and antivirals in the serum of acquired immunodeficiency syndrome patients by micellar liquid chromatography.

  Journal of chromatography. A 20090417

• Improvement of sensitivity and selectivity of high-performance liquid chromatography for anti-retroviral drugs (non-reverse transcriptase inhibitors) by diamond-electrode electrochemical and fluorescence detection.

  Journal of chromatography. A 20090410

• Synthesis and anti-HIV activity of conformationally restricted bicyclic hexahydroisobenzofuran nucleoside analogs.

  Organic & biomolecular chemistry 20090407

• Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV.

  International journal of antimicrobial agents 20090401

• Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3.

  American journal of physiology. Gastrointestinal and liver physiology 20090401

• Non-nucleoside HIV-1 reverse transcriptase inhibitors. Part 13: synthesis of fluorine-containing diaryltriazine derivatives for in vitro anti-HIV evaluation against wild-type strain.

  Chemistry & biodiversity 20090401

• Synthesis and in vitro anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors.

  European journal of medicinal chemistry 20090301

• Influx mechanism of 2',3'-dideoxyinosine and uridine at the blood-placenta barrier.

  Placenta 20090301

• Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy.

  HIV medicine 20090301

• Tenofovir use in human immunodeficiency virus-1-infected children in the United kingdom and Ireland.

  The Pediatric infectious disease journal 20090301

• Roles and mechanisms of human immunodeficiency virus protease inhibitor ritonavir and other anti-human immunodeficiency virus drugs in endothelial dysfunction of porcine pulmonary arteries and human pulmonary artery endothelial cells.

  The American journal of pathology 20090301

• Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus.

  Archives of ophthalmology (Chicago, Ill. : 1960) 20090301

• Permeation of four oral drugs through human intestinal mucosa.

  AAPS PharmSciTech 20090301

• Proximal tubular dysfunction associated with tenofovir and didanosine causing Fanconi syndrome and diabetes insipidus: a report of 3 cases.

  The AIDS reader 20090301

• Editorial comment: tenofovir nephrotoxicity--the disconnect between clinical trials and real-world practice.

  The AIDS reader 20090301

• [ANRS HC 02 RIBAVIC: histo-pathological impact].

  Gastroenterologie clinique et biologique 20090301

• [Treatment of chronic hepatitis C in HIV-infected patients].

  Gastroenterologie clinique et biologique 20090301

• Self-assembled drug delivery systems: Part 3. In vitro/in vivo studies of the self-assembled nanoparticulates of cholesteryl acyl didanosine.

  International journal of pharmaceutics 20090223

• Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990-2007.

  AIDS (London, England) 20090220

• Effect of macrophage depletion on viral DNA rebound following antiretroviral therapy in a murine model of AIDS (MAIDS).

  Antiviral research 20090201

• In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.

  Journal of medical virology 20090201

• Differences in APOBEC3G expression in CD4+ T helper lymphocyte subtypes modulate HIV-1 infectivity.

  PLoS pathogens 20090201

• Medications as a potential source of exposure to phthalates in the U.S. population.

  Environmental health perspectives 20090201

• Efficacy and tolerability of initial antiretroviral therapy: a systematic review.

  AIDS (London, England) 20090128

• Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients.

  AIDS (London, England) 20090102

• Synthesis and anti-HIV studies of 2- and 3-adamantyl-substituted thiazolidin-4-ones.

  European journal of medicinal chemistry 20090101

• Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.

  The Journal of antimicrobial chemotherapy 20090101

• Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.

  The Journal of infectious diseases 20090101

• Metabolic abnormalities associated with HIV infection and antiretroviral therapy.

  Current infectious disease reports 20090101

• Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients.

  PPAR research 20090101

• Fatal HIV encephalitis in HIV-seronegative patients.

  Emerging infectious diseases 20090101

• Pulmonary Kaposi sarcoma in a human immunodeficiency virus - infected woman: a case report.

  Cases journal 20090101

• Antiretroviral-related adipocyte dysfunction and lipodystrophy in HIV-infected patients: Alteration of the PPARγ-dependent pathways.

  PPAR research 20090101

• An analysis of enzyme kinetics data for mitochondrial DNA strand termination by nucleoside reverse transcription inhibitors.

  PLoS computational biology 20090101

• Prescribing and using self-injectable antiretrovirals: how concordant are physician and patient perspectives?

  AIDS research and therapy 20090101

• Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance.

  Retrovirology 20090101

• Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda.

  BMJ (Clinical research ed.) 20090101

• Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria.

  Journal of the International AIDS Society 20090101

• Emergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated child.

  PloS one 20090101

• A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study).

  AIDS research and therapy 20090101

• Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection.

  European journal of medical research 20090101

• Comparative study of the persistence of anti-HIV activity of deoxynucleoside HIV reverse transcriptase inhibitors after removal from culture.

  AIDS research and therapy 20090101

• Quality of life and the impact of drug toxicities in a South African community-based antiretroviral programme.

  Journal of the International AIDS Society 20090101

• Role of atazanavir in the treatment of HIV infection.

  Therapeutics and clinical risk management 20090101

• The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.

  Retrovirology 20090101

• Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.

  Antiviral therapy 20090101

• Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.

  PloS one 20090101

• Risk factors for virological failure and subtherapeutic antiretroviral drug concentrations in HIV-positive adults treated in rural northwestern Uganda.

  BMC infectious diseases 20090101

• Low-cost HIV-1 diagnosis and quantification in dried blood spots by real time PCR.

  PloS one 20090101

• Comparison of brachial and carotid artery ultrasound for assessing extent of subclinical atherosclerosis in HIV: a prospective cohort study.

  AIDS research and therapy 20090101

• Pregnancy outcomes among HIV-infected women undergoing antiretroviral therapy.

  The open AIDS journal 20090101

• Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use.

  PloS one 20090101

• Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.

  PloS one 20090101

• Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study.

  AIDS research and therapy 20090101

• Vision recovery in human immunodeficiency virus-infected patients with optic neuropathy treated with highly active antiretroviral therapy: a case series.

  Indian journal of ophthalmology 20090101

• Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania.

  BMC infectious diseases 20090101

• Predictors of major infections in systemic lupus erythematosus.

  Arthritis research & therapy 20090101

• Host sequence motifs shared by HIV predict response to antiretroviral therapy.

  BMC medical genomics 20090101

• A model and risk score for predicting nevirapine-associated rash among HIV-infected patients: in settings of low CD4 cell counts and resource limitation.

  The open AIDS journal 20090101

• Pharmacotherapy of pediatric and adolescent HIV infection.

  Therapeutics and clinical risk management 20090101

• Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir.

  Therapeutics and clinical risk management 20090101

• Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy.

  BMC infectious diseases 20090101

• Monitoring virologic responses to antiretroviral therapy in HIV-infected adults in Kenya: evaluation of a low-cost viral load assay.

  PloS one 20090101

• Primary HIV-1 drug resistance and polymorphic patterns among injecting drug users (IDUs) in Chennai, Southern India.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20090101

• Evaluation of quantitative liver function tests in HIV-positive patients under anti-retroviral therapy.

  European journal of medical research 20090101

• Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome.

  Retrovirology 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• The impact of combination antiretroviral therapy and its interruption on anxiety, stress, depression and quality of life in Thai patients.

  The open AIDS journal 20090101

• Newly formed cystic lesions for the development of pneumomediastinum in Pneumocystis jirovecii pneumonia.

  BMC infectious diseases 20090101

• Five-year follow up of genotypic resistance patterns in HIV-1 subtype C infected patients in Botswana after failure of thymidine analogue-based regimens.

  Journal of the International AIDS Society 20090101

• Inferring within-patient HIV-1 evolutionary dynamics under anti-HIV therapy using serial virus samples with vSPA.

  BMC bioinformatics 20090101

• Oxidative imbalance in HIV-1 infected patients treated with antiretroviral therapy.

  Journal of biomedicine & biotechnology 20090101

• Treatment interruption after pregnancy: effects on disease progression and laboratory findings.

  Infectious diseases in obstetrics and gynecology 20090101

• The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda.

  Applied health economics and health policy 20090101

• Didanosine withdrawal is associated with improved liver function tests.

  HIV clinical trials 20090101

• The prognosis of late presenters in the era of highly active antiretroviral therapy in serbia.

  The open virology journal 20090101

• Factors influencing global antiretroviral procurement prices.

  BMC public health 20090101

• German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008.

  European journal of medical research 20090101

• Comparison of nucleoside reverse transcriptase inhibitor use as part of first-line therapy in a Serbian and a UK HIV clinic.

  HIV clinical trials 20090101

• Noncirrhotic portal hypertension: another cause of liver disease in HIV patients.

  Annals of hepatology 20090101

• Long term outcomes of antiretroviral therapy in a large HIV/AIDS care clinic in urban South Africa: a prospective cohort study.

  Journal of the International AIDS Society 20090101

• Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome.

  PloS one 20090101

• Correlations between atazanavir C(trough )and hyperbilirubinemia: a case report.

  Journal of medical case reports 20090101

• Virologic suppression, treatment adherence, and improved quality of life on a once-daily efavirenz-based regimen in treatment-Naïve HIV-1-infected patients over 96 weeks.

  HIV clinical trials 20090101

• Resistance and virological response analyses in a three initial treatment strategy trial: a substudy of the INITIO trial.

  HIV clinical trials 20090101

• A Rough Set-Based Model of HIV-1 Reverse Transcriptase Resistome.

  Bioinformatics and biology insights 20090101

• The treatment of chronic hepatitis C virus infection in HIV co-infection.

  European journal of medical research 20090101

• Drug usage evaluation of dapsone.

  Indian journal of pharmaceutical sciences 20090101

• Cardiovascular, renal and liver events associated with human immunodeficiency virus type 1 infection and antiretroviral therapy.

  F1000 medicine reports 20090101

• Rapid and persistent selection of the K103N mutation as a majority quasispecies in a HIV1-patient exposed to efavirenz for three weeks: a case report and review of the literature.

  Journal of medical case reports 20090101

• Treatment, care and support for people co-infected with HIV and hepatitis C: a scoping review.

  Open medicine : a peer-reviewed, independent, open-access journal 20090101

• New approaches in the management of chronic hepatitis B: role of tenofovir.

  Infection and drug resistance 20090101

• Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.

  HIV/AIDS (Auckland, N.Z.) 20090101

• Limited-sampling strategies for anti-infective agents: systematic review.

  The Canadian journal of hospital pharmacy 20090101

• Arthrobacter oxydans as a biocatalyst for purine deamination.

  FEMS microbiology letters 20081201

• Abacavir, Didanosine: myocardial infarction.

  Prescrire international 20081201

• Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reverse-transcriptase inhibitors and those naive to antiretroviral treatment.

  The Journal of infectious diseases 20081115

• Risk factors for mortality in symptomatic hyperlactatemia among HIV-infected patients receiving antiretroviral therapy in a resource-limited setting.

  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20081101

• Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial.

  The Journal of antimicrobial chemotherapy 20081101

• Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.

  The Pediatric infectious disease journal 20081101

• Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study.

  Journal of acquired immune deficiency syndromes (1999) 20081101

• Pediatric efficacy supplement for Videx EC.

  AIDS patient care and STDs 20081101

• FDA notifications. Generic didanosine approved by FDA.

  AIDS alert 20081101

• FDA notifications. FDA approves pediatric efficacy supplement for didanosine capsules.

  AIDS alert 20081101

• Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20081015

• Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements.

  The Journal of antimicrobial chemotherapy 20081001

• Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20081001

• Impact of long-term treatment with neurotoxic dideoxynucleoside antiretrovirals: implications for clinical care in resource-limited settings.

  HIV medicine 20081001

• Morphological transformation of self-assembled nanostructures prepared from cholesteryl acyl didanosine and the optimal formulation of nanoparticulate systems: effects of solvents, acyl chain length and poloxamer 188.

  Journal of colloid and interface science 20081001

• Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy.

  AIDS (London, England) 20081001

• Bullous skin eruption in an HIV patient during antiretroviral drugs therapy.

  Dermatologic therapy 20081001

• Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.

  AIDS research and human retroviruses 20081001

• Disease- and treatment-related predictors of hepatic mitochondrial dysfunction in chronic HIV infection assessed by non-invasive (13)C-methionine breath test diagnostic.

  European journal of medical research 20080922

• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients.

  AIDS (London, England) 20080912

• Abacavir and increased risk of myocardial infarction.

  Lancet (London, England) 20080906

• A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

  Antiviral research 20080901

• Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response.

  The Journal of infectious diseases 20080815

• The nucleoside reverse transcriptase inhibitors didanosine, lamivudine, stavudine and zidovudine show little effect on the virulence of Candida albicans in vitro.

  International journal of antimicrobial agents 20080801

• The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation.

  Journal of acquired immune deficiency syndromes (1999) 20080801

• Diagnosis and management of HIV-associated neuropathy.

  Neurologic clinics 20080801

• Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy.

  Journal of Korean medical science 20080801

• Pegylated interferon 2a and 2b in combination with ribavirin for the treatment of chronic hepatitis C in HIV infected patients.

  Therapeutics and clinical risk management 20080801

• The Relationship Between HIV Infection and Cardiovascular Disease.

  Current cardiology reviews 20080801

• A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand.

  Journal of virological methods 20080701

• The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology.

  Brain : a journal of neurology 20080701

• Neurologic disorders are prevalent in HIV-positive outpatients in the Asia-Pacific region.

  Neurology 20080701

• [Drug-related neuropathies: analysis of the French Adverse Drug Reaction Database 1995-2005].

  Presse medicale (Paris, France : 1983) 20080601

• Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

  Diabetes care 20080601

• Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.

  The Journal of antimicrobial chemotherapy 20080601

• Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080601

• Atriplatrade mark - HIV therapy in one pill.

  Therapeutics and clinical risk management 20080601

• [Tenofovir: pharmacology and interactions].

  Enfermedades infecciosas y microbiologia clinica 20080601

• Highly active antiretroviral HIV therapy-associated fatal lactic acidosis: quantitative and qualitative mitochondrial DNA lesions with mitochondrial dysfunction in multiple organs.

  AIDS (London, England) 20080531

• [Metabolic side effects of antiretroviral therapy].

  Nederlands tijdschrift voor geneeskunde 20080531

• Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.

  Journal of acquired immune deficiency syndromes (1999) 20080501

• Comparative analysis of genetic toxicity of AZT and ddI antiretrovirals in somatic cells of Drosophila melanogaster.

  Environmental and molecular mutagenesis 20080501

• Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy.

  PLoS medicine 20080501

• FDA reviewing safety of Ziagen and Videx.

  The AIDS reader 20080501

• FDA notifications. Large study suggests heart attack risk from use of abacavir or didanosine.

  AIDS alert 20080501

• Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration.

  Lancet (London, England) 20080426

• Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080415

• Effect of food on the antiviral activity of didanosine enteric-coated capsules: a pilot comparative study.

  HIV medicine 20080401

• Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20080401

• Quantification of seven nucleoside/nucleotide reverse transcriptase inhibitors in human plasma by high-performance liquid chromatography with tandem mass-spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080401

• A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.

  British journal of clinical pharmacology 20080401

• Heart attack risk with abacavir and didanosine.

  AIDS patient care and STDs 20080401

• [Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo].

  Bulletin de la Societe de pathologie exotique (1990) 20080401

• Enfuvirtide antiretroviral therapy in HIV-1 infection.

  Therapeutics and clinical risk management 20080401

• Mannosylated gelatin nanoparticles bearing an anti-HIV drug didanosine for site-specific delivery.

  Nanomedicine : nanotechnology, biology, and medicine 20080301

• Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.

  HIV medicine 20080301

• Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20080301

• Determination of abacavir, amprenavir, didanosine, efavirenz, nevirapine, and stavudine concentration in human plasma by MALDI-TOF/TOF.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080301

• Mannan-coated gelatin nanoparticles for sustained and targeted delivery of didanosine: in vitro and in vivo evaluation.

  Acta pharmaceutica (Zagreb, Croatia) 20080301

• Abacavir and didanosine increase the risk of heart attack.

  AIDS patient care and STDs 20080301

• [Screening of HIV-1 replication inhibitors by using pseudotyped virus system].

  Yao xue xue bao = Acta pharmaceutica Sinica 20080301

• Self-assembled drug delivery systems 2. Cholesteryl derivatives of antiviral nucleoside analogues: synthesis, properties and the vesicle formation.

  International journal of pharmaceutics 20080227

• Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131.

  Antimicrobial agents and chemotherapy 20080201

• Cytokine genotype suggests a role for inflammation in nucleoside analog-associated sensory neuropathy (NRTI-SN) and predicts an individual's NRTI-SN risk.

  AIDS research and human retroviruses 20080201

• Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.

  PLoS medicine 20080201

• Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system.

  AIDS patient care and STDs 20080201

• HIV infection and the pancreas: risk factors and potential management guidelines.

  International journal of STD & AIDS 20080201

• The role of antiretroviral therapy in the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study.

  AIDS (London, England) 20080102

• Incidence of pancreatitis in HIV-infected patients: comment on findings in EuroSIDA cohort.

  AIDS (London, England) 20080102

• Neurotoxicity caused by didanosine on cultured dorsal root ganglion neurons.

  Cell biology and toxicology 20080101

• Adenosine 3',5'-cyclic monophosphate (cAMP)-dependent phosphoregulation of mitochondrial complex I is inhibited by nucleoside reverse transcriptase inhibitors.

  Toxicology and applied pharmacology 20080101

• Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients.

  The Journal of antimicrobial chemotherapy 20080101

• Highly active antiretroviral therapy does not affect mitochondrial beta-oxidation of fatty acids: an in vitro study in fibroblasts.

  Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society 20080101

• The incidence of multidrug and full class resistance in HIV-1 infected patients is decreasing over time (2001-2006) in Portugal.

  Retrovirology 20080101

• Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase.

  Retrovirology 20080101

• Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up.

  AIDS research and human retroviruses 20080101

• Adaptation of antiretroviral therapy in human immunodeficiency virus infection with central nervous system involvement.

  Journal of neurovirology 20080101

• Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.

  BMC infectious diseases 20080101

• Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses.

  Retrovirology 20080101

• Longitudinal microarray analysis of cell surface antigens on peripheral blood mononuclear cells from HIV+ individuals on highly active antiretroviral therapy.

  Retrovirology 20080101

• Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for chemical-induced peripheral sensory neuropathies.

  Molecular pain 20080101

• Efficacy and safety of once-daily regimens in the treatment of HIV infection.

  Drugs 20080101

• Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT.

  AIDS research and therapy 20080101

• Acute renal failure in an AIDS patient on tenofovir: a case report.

  Journal of medical case reports 20080101

• Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues.

  Antiviral therapy 20080101

• Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome.

  Antiviral therapy 20080101

• Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk.

  PloS one 20080101

• Pediatric patient with systemic lupus erythematosus & congenital acquired immunodeficiency syndrome: An unusual case and a review of the literature.

  Pediatric rheumatology online journal 20080101

• 2'-deoxy-4'-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants.

  The international journal of biochemistry & cell biology 20080101

• Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.

  Antiviral therapy 20080101

• Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimens.

  Antiviral therapy 20080101

• The risk of developing peripheral neuropathy induced by nucleoside reverse transcriptase inhibitors decreases over time: evidence from the Delta trial.

  Antiviral therapy 20080101

• Molecular evolution of human immunodeficiency virus type 1 upon transmission between human leukocyte antigen disparate donor-recipient pairs.

  PloS one 20080101

• Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.

  Antiviral therapy 20080101

• Hepatic ultrastructural mitochondrial changes prior to antiretroviral therapy in HIV-infected patients in Brazil.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20080101

• Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: a cohort study.

  BMC infectious diseases 20080101

• Prevalence of drug resistance and associated mutations in HIV-positive Puerto Ricans: sex variations.

  Ethnicity & disease 20080101

• Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels.

  PloS one 20080101

• Hepatic steatosis in patients with HIV-Hepatitis C Virus coinfection: is it associated with antiretroviral therapy and more advanced hepatic fibrosis?

  BMC research notes 20080101

• The levator aponeurosis exposed.

  Ophthalmic plastic and reconstructive surgery 20080101

• Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapy.

  PloS one 20080101

• Pathogenesis and treatment of lipodystrophy: what clinicians need to know.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20080101

• Effect of nucleoside and nucleotide reverse transcriptase inhibitors of HIV on endogenous nucleotide pools.

  Antiviral therapy 20080101

• Pharmacokinetics of acetyl-L-carnitine given in single or multiple doses to HIV-1 Infected patients with toxic peripheral polyneuropathy.

  The open AIDS journal 20080101

• Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children.

  BMC infectious diseases 20080101

• Magnitude and complexity of rectal mucosa HIV-1-specific CD8+ T-cell responses during chronic infection reflect clinical status.

  PloS one 20080101

• Interactions between HIV-1 reverse transcriptase and the downstream template strand in stable complexes with primer-template.

  PloS one 20080101

• Ability of online drug databases to assist in clinical decision-making with infectious disease therapies.

  BMC infectious diseases 20080101

• Adherence to highly active antiretroviral therapy and its correlates among HIV infected pediatric patients in Ethiopia.

  BMC pediatrics 20080101

• Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort.

  PloS one 20080101

• Upper gastrointestinal bleeding may unmask didanosine-associated portal hepatopathy in HIV/HCV co-infected patients.

  HIV clinical trials 20080101

• Co-infections. Unexpected liver damage--is ddI to blame?

  TreatmentUpdate 20080101

• High treatment success rates when switching to once daily nevirapine containing antiretroviral therapy.

  The open AIDS journal 20080101

• Harnessing pharmacogenomics to tackle resistance to the 'nucleoside reverse trancripatse inhibitor' backbone of highly active antiretroviral therapy in resource limited settings.

  The open AIDS journal 20080101

• Determinants of Treatment Access in a Population-based Cohort of HIV-positive Men and Women Living in Argentina.

  Journal of the International AIDS Society 20080101

• [Dietary recommendations with practical examples of menus for people living with HIV/AIDS in sub-Saharan Africa].

  The Pan African medical journal 20080101

• [Cordyceps sinensis, a fungi used in the Chinese traditional medicine].

  Revista iberoamericana de micologia 20071231

• Adherence to HAART therapy measured by electronic monitoring in newly diagnosed HIV patients in Botswana.

  European journal of clinical pharmacology 20071201

• Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20071201

• Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine.

  The Journal of infectious diseases 20071201

• Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone.

  Infection 20071201

• Characterization of HIV-1 subtypes and viral antiretroviral drug resistance in men who have sex with men in Beijing, China.

  AIDS (London, England) 20071201

• Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary.

  The Journal of infectious diseases 20071201

• Review of tenofovir-emtricitabine.

  Therapeutics and clinical risk management 20071201

• Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy.

  AIDS (London, England) 20071130

• Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV.

  AIDS (London, England) 20071130

• Reply to Crane et al., 'Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir'.

  AIDS (London, England) 20071130

• [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].

  Zhonghua yi xue za zhi 20071113

• Identification and characterization of new impurity in didanosine.

  Journal of pharmaceutical and biomedical analysis 20071105

• Liposomal formulation of a glycerolipidic prodrug for lymphatic delivery of didanosine via oral route.

  International journal of pharmaceutics 20071101

• Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine treatment failure.

  HIV medicine 20071101

• Evolution of antiretroviral drug costs in Brazil in the context of free and universal access to AIDS treatment.

  PLoS medicine 20071101

• Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients.

  AIDS research and human retroviruses 20071101

• HIV antiretroviral medications and hepatotoxicity.

  Current opinion in HIV and AIDS 20071101

• Management and therapy of chronic hepatitis C in HIV.

  Current opinion in HIV and AIDS 20071101

• Differential sensitivity of thick and thin fibers to HIV and therapy-induced neuropathy.

  Autonomic neuroscience : basic & clinical 20071030

• [Drug-induced pancreatitis].

  Nihon rinsho. Japanese journal of clinical medicine 20071028

• Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry.

  Biomedical chromatography : BMC 20071001

• Effects of apricitabine and other nucleoside reverse transcriptase inhibitors on replication of mitochondrial DNA in HepG2 cells.

  Antiviral research 20071001

• Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosine.

  Journal of acquired immune deficiency syndromes (1999) 20071001

• Pharmacokinetics of coadministered ritonavir-boosted elvitegravir and zidovudine, didanosine, stavudine, or abacavir.

  Journal of acquired immune deficiency syndromes (1999) 20071001

• Polymorphism and drug selected mutations of reverse transcriptase gene in 102 HIV-1 infected patients living in China.

  Journal of medical virology 20071001

• Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.

  Therapeutic drug monitoring 20071001

• Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study.

  AIDS research and human retroviruses 20071001

• Impact of the number of failed therapeutic regimes on the development of resistance mutations to HIV-1 in northeast Brazil.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20071001

• Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.

  AIDS (London, England) 20070912

• Erythrocebus patas monkey offspring exposed perinatally to NRTIs sustain skeletal muscle mitochondrial compromise at birth and at 1 year of age.

  Toxicological sciences : an official journal of the Society of Toxicology 20070901

• Mutations at 65 and 70 within the context of a Q151M cluster in human immunodeficiency virus type 1 reverse transcriptase impact the susceptibility to the different nucleoside reverse transcriptase inhibitors in distinct ways.

  Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 20070901

• Prevalence of and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006.

  HIV medicine 20070901

• Adverse events experienced by three children taking tenofovir and didanosine in combination.

  HIV medicine 20070901

• Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients.

  The Journal of infectious diseases 20070901

• Nucleoside reverse-transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record era.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070901

• Steatohepatitis in HIV-infected subjects: pathogenesis, clinical impact and implications in clinical management.

  Current HIV research 20070901

• Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase.

  Journal of acquired immune deficiency syndromes (1999) 20070815

• Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.

  Journal of acquired immune deficiency syndromes (1999) 20070815

• US and UK versions of the EQ-5D preference weights: does choice of preference weights make a difference?

  Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20070801

• Emergence of human immunodeficiency virus type 1 variants containing the Q151M complex in children receiving long-term antiretroviral chemotherapy.

  Antiviral research 20070801

• Evolution of a novel 5-amino-acid insertion in the beta3-beta4 loop of HIV-1 reverse transcriptase.

  Virology 20070801

• Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression.

  Brain : a journal of neurology 20070801

• Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in Randomized Evaluation of Strategic Intervention in multidrug-resiStant patients with tipranavir (RESIST) studies.

  Journal of acquired immune deficiency syndromes (1999) 20070801

• Long-term safety and efficacy of a once-daily regimen of emtricitabine, didanosine, and efavirenz in HIV-infected, therapy-naive children and adolescents: Pediatric AIDS Clinical Trials Group Protocol P1021.

  Pediatrics 20070801

• Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial.

  AIDS research and human retroviruses 20070801

• Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz.

  AIDS research and human retroviruses 20070801

• Role of posaconazole in the management of oropharyngeal and esophageal candidiasis.

  Therapeutics and clinical risk management 20070801

• The renaissance of fixed dose combinations: Combivir.

  Therapeutics and clinical risk management 20070801

• Review of tipranavir in the treatment of drug-resistant HIV.

  Therapeutics and clinical risk management 20070801

• More on the treatment-tropism relationship: the impact of prior antiretroviral treatment on HIV coreceptor tropism among subjects entering AIDS clinical trials group 175.

  The Journal of infectious diseases 20070715

• A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070715

• Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir.

  AIDS (London, England) 20070711

• Response to Mallet et al., 'Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients'.

  AIDS (London, England) 20070711

• Nodular regenerative hyperplasia: a new serious antiretroviral drugs side effect?

  AIDS (London, England) 20070711

• Synthesis and anti-HIV studies of 2-adamantyl-substituted thiazolidin-4-ones.

  European journal of medicinal chemistry 20070701

• Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20070701

• Forecast of demand for antiretroviral drugs in low and middle-income countries: 2007-2008.

  AIDS (London, England) 20070701

• The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa.

  AIDS research and human retroviruses 20070701

• A 21-base pair insertion/duplication at codon 69 of the HIV type 1 reverse transcriptase in a patient undergoing multiple nucleoside therapy.

  AIDS research and human retroviruses 20070701

• Hepatotoxicity and liver disease in the context of HIV therapy.

  Current opinion in HIV and AIDS 20070701

• CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.

  The Journal of antimicrobial chemotherapy 20070601

• Therapeutic issues in HIV/HCV-coinfected patients.

  Journal of viral hepatitis 20070601

• The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine.

  Journal of acquired immune deficiency syndromes (1999) 20070601

• FDA notifications. FDA grants approval for generic didanosine for oral solution.

  AIDS alert 20070601

• Skin and skin structure infections: treatment with newer generation fluoroquinolones.

  Therapeutics and clinical risk management 20070601

• Possible allergic cross-reaction to didanosine and tenofovir in an HIV-1-infected woman.

  AIDS (London, England) 20070511

• Determination of 19 antiretroviral agents in pharmaceuticals or suspected products with two methods using high-performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070501

• Development and evaluation of an oligonucleotide ligation assay for detection of drug resistance-associated mutations in the human immunodeficiency virus type 2 pol gene.

  Journal of clinical microbiology 20070501

• Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.

  Journal of acquired immune deficiency syndromes (1999) 20070501

• Antiretroviral therapies associated with lipoatrophy in HIV-infected women.

  AIDS patient care and STDs 20070501

• FDA notifications. FDA grants approval for generic didanosine for oral solution.

  AIDS alert 20070501

• Synthesis and biological evaluation of two glycerolipidic prodrugs of didanosine for direct lymphatic delivery against HIV.

  Bioorganic & medicinal chemistry letters 20070415

• Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.

  The Journal of antimicrobial chemotherapy 20070401

• [Sustained spontaneous remission of chronic hepatitis C coinfection in HIV].

  Enfermedades infecciosas y microbiologia clinica 20070401

• Generic DDI oral solution approved.

  AIDS patient care and STDs 20070401

• Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.

  Pediatrics 20070301

• Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20070301

• CD4+ cell count decline despite HIV suppression: a probable didanosine-valganciclovir interaction.

  The Annals of pharmacotherapy 20070301

• [Antiretrovirals].

  Nihon rinsho. Japanese journal of clinical medicine 20070227

• Metabolic and anthropometric changes one year after switching from didanosine/stavudine to tenofovir in HIV-infected patients.

  European journal of medical research 20070226

• Hydroxyurea and interleukin-6 synergistically reactivate HIV-1 replication in a latently infected promonocytic cell line via SP1/SP3 transcription factors.

  The Journal of biological chemistry 20070209

• Synthesis and anti-HIV activity evaluation of 1-[(alkenyl or alkynyl or alkyloxy)methyl]-5-alkyl-6-(1-naphthoyl)-2,4-pyrimidinediones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.

  European journal of medicinal chemistry 20070201

• Modulation of human BCRP (ABCG2) activity by anti-HIV drugs.

  The Journal of antimicrobial chemotherapy 20070201

• Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infection.

  The Journal of infectious diseases 20070201

• [Severe thrombocytopenia and human immunodeficiency virus infection. Report of two cases and review].

  Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia 20070201

• Synthesis and in vitro anti-HIV activities of didanosine prodrugs.

  Journal of enzyme inhibition and medicinal chemistry 20070201

• Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity.

  Environmental and molecular mutagenesis 20070101

• Application of the convection-dispersion equation to modelling oral drug absorption.

  Bulletin of mathematical biology 20070101

• A new model for the population pharmacokinetics of didanosine in healthy subjects.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20070101

• Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy.

  AIDS research and human retroviruses 20070101

• Virostatics: a new class of anti-HIV drugs.

  Current medicinal chemistry 20070101

• Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338).

  AIDS research and therapy 20070101

• Relative mutagenic potencies of several nucleoside analogs, alone or in drug pairs, at the HPRT and TK loci of human TK6 lymphoblastoid cells.

  Environmental and molecular mutagenesis 20070101

• Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.

  BMC pediatrics 20070101

• HIV/AIDS drugs for Sub-Saharan Africa: how do brand and generic supply compare?

  PloS one 20070101

• Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.

  Retrovirology 20070101

• Evaluation of human immunodeficiency virus type 1-infected Chinese patients treated with highly active antiretroviral therapy for two years.

  Viral immunology 20070101

• Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: a case report.

  Journal of medical case reports 20070101

• A virological benefit from an induction/maintenance strategy: the Forte trial.

  Antiviral therapy 20070101

• AIDS in the Third World: how to stop the HIV infection?

  Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101

• Anti-HIV drugs.

  Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie 20070101

• Healthcare utilization of patients accessing an African national treatment program.

  BMC health services research 20070101

• Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20070101

• Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial).

  Antiviral therapy 20070101

• Didanosine enteric-coated capsule: current role in patients with HIV-1 infection.

  Drugs 20070101

• Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus-1 (HIV-1) infected pediatric patients: a cross-sectional study.

  AIDS research and therapy 20070101

• Electrospray tandem mass spectroscopic characterisation of 18 antiretroviral drugs and simultaneous quantification of 12 antiretrovirals in plasma.

  Rapid communications in mass spectrometry : RCM 20070101

• Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals.

  PloS one 20070101

• Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin.

  Antiviral therapy 20070101

• Update on the treatment of chronic hepatitis C in HIV-infected patients.

  AIDS reviews 20070101

• The HIV RNA setpoint theory revisited.

  Retrovirology 20070101

• Mycobacterium avium complex immune reconstitution inflammatory syndrome: long term outcomes.

  Journal of translational medicine 20070101

• Utilization and spending trends for antiretroviral medications in the U.S. Medicaid program from 1991 to 2005.

  AIDS research and therapy 20070101

• Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES).

  HIV clinical trials 20070101

• Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors.

  Antiviral therapy 20070101

• Rapid CD4 decline after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy in a resource-limited setting.

  AIDS research and therapy 20070101

• Seroprevalence of hepatitis B and C viral co-infections among children infected with human immunodeficiency virus attending the paediatric HIV care and treatment center at Muhimbili National Hospital in Dar-es-Salaam, Tanzania.

  BMC public health 20070101

• Synthesis of 2',3'-dideoxyinosine via radical deoxygenation.

  Nucleosides, nucleotides & nucleic acids 20070101

• Poor efficacy and tolerability of stavudine, didanosine, and efavirenz-based regimen in treatment-naive patients in Senegal.

  MedGenMed : Medscape general medicine 20070101

• The balance between NRTI discrimination and excision drives the susceptibility of HIV-1 RT mutants K65R, M184V and K65r+M184V.

  Antiviral chemistry & chemotherapy 20070101

• Clinical implications of mutations at reverse transcriptase codon 135 on response to NNRTI-based therapy.

  The open virology journal 20070101

• Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal.

  Journal of the International AIDS Society 20070101

• Pancreatitis following Olanzapine Therapy: A Report of Three Cases.

  Case reports in gastroenterology 20070101

• Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.

  Journal of acquired immune deficiency syndromes (1999) 20061215

• Severity of the toxicity associated with combinations that include didanosine plus stavudine in HIV-infected experienced patients.

  Journal of acquired immune deficiency syndromes (1999) 20061215

• Protective effect of acetyl-L-carnitine against oxidative stress induced by antiretroviral drugs.

  FEBS letters 20061211

• Didanosine-induced retinopathy in adults can be reversible.

  Eye (London, England) 20061201

• Nucleoside reverse transcriptase inhibitors prevent HIV protease inhibitor-induced atherosclerosis by ubiquitination and degradation of protein kinase C.

  American journal of physiology. Cell physiology 20061201

• Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey).

  Journal of acquired immune deficiency syndromes (1999) 20061201

• In vitro human immunodeficiency virus type 1 resistance selections with combinations of tenofovir and emtricitabine or abacavir and lamivudine.

  Antimicrobial agents and chemotherapy 20061201

• Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.

  The Journal of antimicrobial chemotherapy 20061201

• In-vitro transport characteristics discriminate wild-type ABCB1 (MDR1) from ALA893SER and ALA893THR polymorphisms.

  Pharmacogenetics and genomics 20061201

• Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients.

  Expert review of anti-infective therapy 20061201

• Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV--focus on pegylated interferon-alpha.

  International journal of nanomedicine 20061201

• Synthesis of novel L-N-MCd4T as a potent anti-HIV agent.

  Organic & biomolecular chemistry 20061121

• In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cells.

  Antimicrobial agents and chemotherapy 20061101

• Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection.

  PLoS medicine 20061101

• Adherence strategies. FDA approves ddI generic version.

  AIDS alert 20061101

• Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors.

  AIDS research and human retroviruses 20061101

• Establishment of a rodent model of HIV-associated sensory neuropathy.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20061004

• Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.

  HIV medicine 20061001

• Biomedical issues of dietary fiber beta-glucan.

  Journal of Korean medical science 20061001

• Multi-drug resistant HIV-1 reverse transcriptase genotype in children treated with dual nucleoside reverse transcriptase inhibitors (NRTIs).

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20061001

• Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations.

  AIDS (London, England) 20060911

• Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand.

  The Journal of antimicrobial chemotherapy 20060901

• Non-nucleoside HIV-1 reverse transcriptase inhibitors, Part 7. Synthesis, antiviral activity, and 3D-QSAR investigations of novel 6-(1-naphthoyl) HEPT analogues.

  Chemical & pharmaceutical bulletin 20060901

• Virological and immunological responses of efavirenz-based HAART regimen initiated in HIV-infected patients at CD4 < 100 versus CD4 > or = 100 cells/mm3.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20060901

• Surrogate outcomes in neurology, psychiatry, and psychopharmacology.

  Dialogues in clinical neuroscience 20060901

• [Renal toxicity in HIV-infected patients receiving HAART including tenofovir].

  Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive 20060901

• Adverse effects of antiretroviral therapy in HIV-1 infected children.

  Journal of tropical pediatrics 20060801

• Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060801

• Hypokalemia in HIV patients on tenofovir.

  AIDS (London, England) 20060801

• Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.

  Antimicrobial agents and chemotherapy 20060801

• Immunological and virological effects of structured treatment interruptions following exposure to hydroxyurea plus didanosine.

  AIDS research and human retroviruses 20060801

• Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.

  Expert review of anti-infective therapy 20060801

• Therapeutic potential of chloroquine added to zidovudine plus didanosine for HIV-1 infected children.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20060801

• National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines?

  AIDS (London, England) 20060713

• Hemochromatosis (HFE) gene mutations and peripheral neuropathy during antiretroviral therapy.

  AIDS (London, England) 20060713

• Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.

  The Journal of antimicrobial chemotherapy 20060701

• 1'S-1'-acetoxychavicol acetate isolated from Alpinia galanga inhibits human immunodeficiency virus type 1 replication by blocking Rev transport.

  The Journal of general virology 20060701

• Virologic and immunologic efficacy of the tenofovir/didanosine/lamivudine regimen.

  Journal of acquired immune deficiency syndromes (1999) 20060701

• Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir.

  Pediatric nephrology (Berlin, Germany) 20060701

• Nephrotoxicity as a complication of antiretroviral therapy.

  Advances in chronic kidney disease 20060701

• Distal sensory polyneuropathy in HIV-positive patients in the HAART era: an entity underestimated by clinical examination.

  International journal of STD & AIDS 20060701

• A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST study.

  PLoS clinical trials 20060701

• HIV-1 reverse transcriptase (RT) genotypic patterns and treatment characteristics associated with the K65R RT mutation.

  HIV medicine 20060701

• Hepatic steatosis and ddI, d4T use.

  IAPAC monthly 20060701

• Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060615

• HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.

  AIDS (London, England) 20060612

• Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20060601

• Penetration of didanosine in semen of HIV-1-infected men.

  The Journal of antimicrobial chemotherapy 20060601

• Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapy.

  Clinical chemistry 20060601

• Getting it right: being smarter about clinical trials.

  PLoS medicine 20060601

• Antiviral activity of nucleoside analogues during short-course monotherapy or dual therapy: its role in preventing HIV infection in infants.

  Journal of acquired immune deficiency syndromes (1999) 20060601

• The role of hydroxyurea in enhancing the virologic control achieved through structured treatment interruption in primary HIV infection: final results from a randomized clinical trial (Pulse).

  Journal of acquired immune deficiency syndromes (1999) 20060601

• Severe liver disease associated with prolonged exposure to antiretroviral drugs.

  Journal of acquired immune deficiency syndromes (1999) 20060601

• Antiretroviral drug resistance and routine therapy, Cameroon.

  Emerging infectious diseases 20060601

• Prenatal developmental toxicity evaluation of 2',3'-dideoxyinosine (ddI) and 2',3'-didehydro-3'-deoxythymidine (d4T) co-administered to Swiss Albino (CD-1) mice.

  Birth defects research. Part B, Developmental and reproductive toxicology 20060601

• Analysis and validation of the phosphorylated metabolites of two anti-human immunodeficiency virus nucleotides (stavudine and didanosine) by pressure-assisted CE-ESI-MS/MS in cell extracts: sensitivity enhancement by the use of perfluorinated acids and alcohols as coaxial sheath-liquid make-up constituents.

  Electrophoresis 20060601

• Management of hepatitis C virus coinfection in HIV-infected persons.

  The AIDS reader 20060601

• A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein-Barr virus in adults with human immunodeficiency virus-1.

  British journal of cancer 20060522

• An additive/subtractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20060501

• Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.

  The Journal of antimicrobial chemotherapy 20060501

• Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20060501

• Sensory neuropathy in human immunodeficiency virus/acquired immunodeficiency syndrome patients: protease inhibitor-mediated neurotoxicity.

  Annals of neurology 20060501

• Detection of lipoatrophy in human immunodeficiency virus-1-infected children treated with highly active antiretroviral therapy.

  The Pediatric infectious disease journal 20060501

• [Clinical and subclinical neuropathy in patients with human immunodeficiency virus receiving antiretroviral therapy].

  Revista de neurologia 20060501

• The pricing and procurement of antiretroviral drugs: an observational study of data from the Global Fund.

  Bulletin of the World Health Organization 20060501

• Nucleotide excision repair and template-independent addition by HIV-1 reverse transcriptase in the presence of nucleocapsid protein.

  The Journal of biological chemistry 20060428

• Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial.

  Journal of acquired immune deficiency syndromes (1999) 20060415

• Short-term safety and tolerability of didanosine combined with high- versus low-dose tenofovir disproxil fumarate in ambulatory HIV-1-infected persons.

  AIDS patient care and STDs 20060401

• Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir.

  AIDS research and human retroviruses 20060401

• Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort.

  Neurology 20060328

• 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.

  AIDS (London, England) 20060321

• A rare HIV reverse transcriptase mutation, K65N, confers reduced susceptibility to tenofovir, lamivudine and didanosine.

  AIDS (London, England) 20060321

• Associations among race/ethnicity, ApoC-III genotypes, and lipids in HIV-1-infected individuals on antiretroviral therapy.

  PLoS medicine 20060301

• Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060301

• Chronic hepatitis C in HIV-infected patients: those who more need therapy are those who respond less.

  Infectious disorders drug targets 20060301

• Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20060202

• In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.

  Antimicrobial agents and chemotherapy 20060201

• JPN Guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis.

  Journal of hepato-biliary-pancreatic surgery 20060201

• Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?

  PLoS pathogens 20060201

• [Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection].

  Revista clinica espanola 20060201

• Study of efavirenz over 96 weeks shows durability, efficacious regimen. Results from 48-96 weeks essentially same.

  AIDS alert 20060201

• Potency of stampidine against multi-nucleoside reverse transcriptase inhibitor resistant human immunodeficiency viruses.

  Arzneimittel-Forschung 20060201

• Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060115

• Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment: lessons from Mexico.

  AIDS (London, England) 20060102

• Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates.

  Biostatistics (Oxford, England) 20060101

• Suspected drug-induced liver fatalities reported to the WHO database.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20060101

• Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and non-nucleoside inhibitors.

  Journal of medical virology 20060101

• Depletion of mitochondrial DNA copies/cell in peripheral blood mononuclear cells in HIV-1-infected treatment-naïve patients.

  HIV medicine 20060101

• Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20060101

• Antiviral hepatitis and antiretroviral drug interactions.

  Journal of hepatology 20060101

• The distribution of the anti-HIV drug, tenofovir (PMPA), into the brain, CSF and choroid plexuses.

  Cerebrospinal fluid research 20060101

• A simplified weight-based method for pediatric drug dosing for zidovudine and didanosine in resource-limited settings.

  The Pediatric infectious disease journal 20060101

• Longitudinal study on mitochondrial effects of didanosine-tenofovir combination.

  AIDS research and human retroviruses 20060101

• [Mitochondrial cytopathies associated with HIV infection].

  Revue neurologique 20060101

• Absence of seroreversion in 80 HAART-treated HIV-1 seropositive patients with at least five-years undetectable plasma HIV-1 viral load.

  AIDS research and therapy 20060101

• A prospective study of hearing changes after beginning zidovudine or didanosine in HIV-1 treatment-naïve people.

  BMC infectious diseases 20060101

• Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions.

  Antiviral therapy 20060101

• Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.

  Antiviral therapy 20060101

• DR_SEQAN: a PC/Windows-based software to evaluate drug resistance using human immunodeficiency virus type 1 genotypes.

  BMC infectious diseases 20060101

• CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa.

  BMC infectious diseases 20060101

• Cerebrospinal fluid HIV-1 RNA, intrathecal immunoactivation, and drug concentrations after treatment with a combination of saquinavir, nelfinavir, and two nucleoside analogues: the M61022 study.

  BMC infectious diseases 20060101

• Clinically stable treatment-experienced adults receiving tenofovir and didanosine.

  HIV clinical trials 20060101

• The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations.

  Antiviral therapy 20060101

• Subclinical hypothyroidism in HIV-infected patients is not an autoimmune disease.

  Hormone research 20060101

• A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil.

  AIDS research and therapy 20060101

• Determination of didanosine in maternal plasma, amniotic fluid, fetal and placental tissues by high-performance liquid chromatography-tandem mass spectrometry.

  Biomedical chromatography : BMC 20060101

• 2'-deoxy-4'-C-ethynyl-2-fluoroadenosine, a nucleoside reverse transcriptase inhibitor, is highly potent against all human immunodeficiency viruses type 1 and has low toxicity.

  Chemical record (New York, N.Y.) 20060101

• Tenofovir-containing nucleoside/nucleotide-only antiretroviral maintenance therapy: decision making and virological outcome.

  HIV clinical trials 20060101

• Bioavailability study of two oral formulations of didanosine in healthy volunteers.

  Arzneimittel-Forschung 20060101

• Oral manifestations of HIV infection in children and adults receiving highly active anti-retroviral therapy [HAART] in Dar es Salaam, Tanzania.

  BMC oral health 20060101

• 36 year old man presenting with pancreatitis and a history of recent commencement of Orlistat case report.

  Nutrition journal 20060101

• [Immunological effectiveness of the nucleoside/nucleotide analog combinations, tenofovir + lamivudine, didanosine + lamivudine and tenofovir + didanosine, in patients with HIV infection and sustained viral suppression].

  Enfermedades infecciosas y microbiologia clinica 20060101

• Mitochondrial (mt)DNA changes in tissue may not be reflected by depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected patients.

  Antiviral therapy 20060101

• Is oxygen a key factor in the lipodystrophy phenotype?

  Lipids in health and disease 20060101

• A cohort study of the food effect on virological failure and treatment discontinuation in patients on HAART containing didanosine enteric-coated capsules (FOODDIe Study).

  HIV clinical trials 20060101

• Limitations of a simplification antiretroviral strategy for HIV-infected patients with decreasing adherence to a protease inhibitor regimen.

  HIV clinical trials 20060101

• Etravirine: R165335, TMC 125, TMC-125, TMC125.

  Drugs in R&D 20060101

• Tenofovir plus didanosine as Nrti backbone in HIV-infected subjects.

  Current medicinal chemistry 20060101

• Therapeutic challenges in hepatitis C-infected injection drug using patients.

  Harm reduction journal 20060101

• [Acute renal failure and proximal renal tubular dysfuntion in a patient with acquired immunodeficiency syndrome treated with tenofovir].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20060101

• Longitudinal changes in HIV-specific IFN-gamma secretion in subjects who received Remune vaccination prior to treatment interruption.

  Journal of immune based therapies and vaccines 20060101

• The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa--a primary data analysis.

  Cost effectiveness and resource allocation : C/E 20060101

• An immunological comparison of third companion in advanced drug-naive HIV-infected patients.

  HIV clinical trials 20060101

• Strong HIV-1-specific T cell responses in HIV-1-exposed uninfected infants and neonates revealed after regulatory T cell removal.

  PloS one 20060101

• Use of taste-masking product, FLAVORx, to assist Thai children to ingest generic antiretrovirals.

  AIDS research and therapy 20060101

• Using cost-effectiveness analyses to inform policy: the case of antiretroviral therapy in Thailand.

  Cost effectiveness and resource allocation : C/E 20060101

• Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of variability and frequent exposure to contraindicated drugs.

  Antiviral therapy 20060101

• Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine.

  Antiviral therapy 20060101

• Disease Management - Constructing Optimal NRTI-Based Combinations: Past, Present, and Future.

  Journal of the International AIDS Society 20060101

• Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051215

• Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20051215

• New paradigms in the management of HIV and hepatitis C virus coinfection.

  Current opinion in infectious diseases 20051201

• Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine.

  Journal of clinical pharmacology 20051201

• Chronic hepatitis C in patients with HIV/AIDS: a new challenge in antiviral therapy.

  The Journal of antimicrobial chemotherapy 20051201

• Allosteric modulation of anti-HIV drug and ferric heme binding to human serum albumin.

  The FEBS journal 20051201

• Hepatitis C and didanosine: risk of lactic acidosis.

  Prescrire international 20051201

• Treatment of hepatitis C in HIV-infected patients: regularly reassess the benefits and risks.

  Prescrire international 20051201

• Should tenofovir ever be used in association with didanosine?

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20051201

• T-cell response of advanced aids patients after highly active antiretroviral therapy.

  Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih 20051201

• Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality.

  Therapeutics and clinical risk management 20051201

• [Adverse effects of antiretroviral treatments].

  Presse medicale (Paris, France : 1983) 20051119

• Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir.

  AIDS (London, England) 20051118

• A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT.

  AIDS (London, England) 20051104

• Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.

  AIDS (London, England) 20051104

• Method development and validation for the analysis of didanosine using micellar electrokinetic capillary chromatography.

  Electrophoresis 20051101

• Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy.

  Journal of acquired immune deficiency syndromes (1999) 20051101

• Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study).

  Journal of acquired immune deficiency syndromes (1999) 20051101

• Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana.

  Journal of acquired immune deficiency syndromes (1999) 20051101

• Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.

  HIV medicine 20051101

• Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 20051101

• A direct comparison of drug susceptibility to HIV type 1 from antiretroviral experienced subjects as assessed by the antivirogram and PhenoSense assays and by seven resistance algorithms.

  AIDS research and human retroviruses 20051101

• In vitro mutagenicity studies of the antiretrovirals AZT, Didanosine, and 3TC and a plant antiviral extract Secomet-V derived from the Trifollium species.

  Annals of the New York Academy of Sciences 20051101

• Initiation of antiretroviral treatment with dual nucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected infants with less advanced disease in a resource-limited setting: a multi-center study in Thailand 1998-2000.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20051101

• High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir.

  AIDS (London, England) 20051014

• Determination of antiretroviral agents in human serum by capillary electrophoresis.

  Journal of chromatography. A 20051014

• Newly designed six-membered azasugar nucleotide-containing phosphorothioate oligonucleotides as potent human immunodeficiency virus type 1 inhibitors.

  Antimicrobial agents and chemotherapy 20051001

• Non-nucleoside HIV reverse transcriptase inhibitors, Part 6[1]: synthesis and anti-HIV activity of novel 2-[(arylcarbonylmethyl)thio]-6-arylthio DABO analogues.

  Archiv der Pharmazie 20051001

• Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.

  The Pediatric infectious disease journal 20051001

• Treatment of hepatitis C virus and human immunodeficiency virus co-infection.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20051001

• Estimating the genetic component (RGC) in pharmacokinetic variability of the antiretroviral didanosine among healthy Brazilians.

  AIDS (London, England) 20051001

• When do children convert from liquid antiretroviral to solid formulations?

  Pharmacy world & science : PWS 20051001

• Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050915

• Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study.

  AIDS (London, England) 20050902

• Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir.

  AIDS (London, England) 20050902

• Risk factors for and outcome of hyperlactatemia in HIV-infected persons: is there a need for routine lactate monitoring?

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050901

• Drug-induced pancreatitis: an update.

  Journal of clinical gastroenterology 20050901

• Pharmacokinetics of antivirals in neonate.

  Early human development 20050901

• Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy.

  Journal of acquired immune deficiency syndromes (1999) 20050901

• The pharmacological potential of mushrooms.

  Evidence-based complementary and alternative medicine : eCAM 20050901

• Severe toxicity associated with the combination of tenofovir and didanosine: case report and review.

  International journal of STD & AIDS 20050901

• Seminal reservoirs during an HIV type 1 eradication trial.

  AIDS research and human retroviruses 20050901

• Long-term complete remission of laryngeal Kaposi's sarcoma after palliative radiotherapy.

  Nature clinical practice. Oncology 20050901

• Transfer of antivirals across the human placenta.

  Early human development 20050801

• Anti-human immunodeficiency virus type 1 activity and resistance profile of 2',3'-didehydro-3'-deoxy-4'-ethynylthymidine in vitro.

  Antimicrobial agents and chemotherapy 20050801

• Nonnucleoside HIV-1 reverse-transcriptase inhibitors, part 5. Synthesis and anti-HIV-1 activity of novel 6-naphthylthio HEPT analogues.

  Chemical & pharmaceutical bulletin 20050801

• Acanthosis nigricans as an adverse effect of highly active antiretroviral therapy in an adolescent girl with human immunodeficiency virus infection.

  The Pediatric infectious disease journal 20050801

• Tenofovir and didanosine: a dangerous liaison.

  The AIDS reader 20050801

• Nucleoside/nucleotide backbones for the treatment of HIV infection.

  Current opinion in investigational drugs (London, England : 2000) 20050801

• Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors.

  Journal of neurovirology 20050801

• Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus.

  Pharmacotherapy 20050801

• Simultaneous analysis of several antiretroviral nucleosides in rat-plasma by high-performance liquid chromatography with UV using acetic acid/hydroxylamine buffer Test of this new volatile medium-pH for HPLC-ESI-MS/MS.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050725

• Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms.

  AIDS (London, England) 20050722

• Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial.

  AIDS (London, England) 20050722

• Development and validation of a HPLC-UV method for the determination in didanosine tablets.

  Journal of pharmaceutical and biomedical analysis 20050715

• Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050715

• Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen.

  AIDS (London, England) 20050701

• HAART with didanosine once versus twice daily: adherence and efficacy.

  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20050701

• Natural resistance of human immunodeficiency virus type 2 to zidovudine.

  Virology 20050605

• [Antiretroviral agents in HIV-infected patients with cirrhosis].

  Presse medicale (Paris, France : 1983) 20050604

• Estimating HIV evolutionary pathways and the genetic barrier to drug resistance.

  The Journal of infectious diseases 20050601

• Effects of HIV Q151M-associated multi-drug resistance mutations on the activities of (-)-beta-D-1',3'-dioxolan guanine.

  Antiviral research 20050601

• Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned.

  Journal of acquired immune deficiency syndromes (1999) 20050601

• Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20050601

• A long-term survival case of small cell lung cancer in an HIV-infected patient.

  Japanese journal of clinical oncology 20050601

• Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.

  The Pediatric infectious disease journal 20050601

• Incidence of acute pancreatitis and nucleoside reverse transcriptase inhibitors usage.

  International journal of STD & AIDS 20050601

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050601

• Fanconi syndrome associated with didanosine therapy.

  AIDS (London, England) 20050520

• Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20050501

• Mechanism of anti-human immunodeficiency virus activity of beta-D-6-cyclopropylamino-2',3'-didehydro-2',3'-dideoxyguanosine.

  Antimicrobial agents and chemotherapy 20050501

• The durability of virological success of tenofovir and didanosine dosed at either 400 or 250 mg once daily.

  HIV medicine 20050501

• Emerging anti-HIV drugs.

  Expert opinion on emerging drugs 20050501

• High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir.

  AIDS (London, England) 20050429

• [Didanosine--stability as backbone drug].

  MMW Fortschritte der Medizin 20050425

• Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes.

  The Journal of biological chemistry 20050422

• A one-year clinical trial using didanosine, stavudine and nevirapine for highly active antiretroviral therapy.

  Chinese medical journal 20050405

• Gene repair in mammalian cells is stimulated by the elongation of S phase and transient stalling of replication forks.

  DNA repair 20050404

• Nucleotide specificity of HIV-1 reverse transcriptases with amino acid substitutions affecting Ala-114.

  The Biochemical journal 20050401

• Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays.

  Journal of acquired immune deficiency syndromes (1999) 20050401

• [Toxic epidermal necrolysis associated with abacavir].

  Enfermedades infecciosas y microbiologia clinica 20050401

• Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.

  PLoS medicine 20050401

• Emtricitabine: new preparation. An antiretroviral very similar to lamivudine.

  Prescrire international 20050401

• Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.

  AIDS research and human retroviruses 20050401

• Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.

  AIDS (London, England) 20050324

• [Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].

  Zhonghua yi xue za zhi 20050323

• Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.

  The Journal of infectious diseases 20050315

• Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial.

  The Journal of infectious diseases 20050315

• Effects of of didanosine-related depletion of mtDNA in human T lymphocytes.

  The Journal of infectious diseases 20050315

• Serum neopterin, an immune activation marker, independently predicts disease progression in advanced HIV-1 infection.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050315

• Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20050301

• In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase.

  Antimicrobial agents and chemotherapy 20050301

• Generic didanosine gets approved.

  AIDS patient care and STDs 20050301

• Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050225

• Expression of deoxynucleotide carrier is not associated with the mitochondrial DNA depletion caused by anti-HIV dideoxynucleoside analogs and mitochondrial dNTP uptake.

  Molecular pharmacology 20050201

• Therapeutic response of HIV-1 subtype C in African patients coinfected with either Mycobacterium tuberculosis or human herpesvirus-8.

  The Journal of infectious diseases 20050201

• Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers.

  Journal of clinical pharmacology 20050201

• Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine.

  Journal of acquired immune deficiency syndromes (1999) 20050201

• Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy.

  Clinical nutrition (Edinburgh, Scotland) 20050201

• Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.

  Seminars in liver disease 20050201

• Tipranavir: a novel second-generation nonpeptidic protease inhibitor.

  Expert review of anti-infective therapy 20050201

• Human immunodeficiency virus infection: personal experience in changes in head and neck manifestations due to recent antiretroviral therapies.

  Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale 20050201

• Hydroxyurea exerts a cytostatic but not immunosuppressive effect on T lymphocytes.

  AIDS (London, England) 20050128

• Prolonged treatment interruption in chronic HIV infection: a new strategy?

  AIDS (London, England) 20050128

• Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine.

  AIDS (London, England) 20050128

• Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV outpatient study cohort.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050101

• Development and validation of a liquid chromatographic/tandem mass spectrometric assay for the quantitation of nucleoside HIV reverse transcriptase inhibitors in biological matrices.

  Journal of mass spectrometry : JMS 20050101

• Combination of inhibitors of lymphocyte activation (hydroxyurea, trimidox, and didox) and reverse transcriptase (didanosine) suppresses development of murine retrovirus-induced lymphoproliferative disease.

  Antiviral research 20050101

• Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.

  HIV medicine 20050101

• Pancreatic exocrine insufficiency in HIV-positive patients.

  HIV medicine 20050101

• Novel mutual pro-drugs of 2',3'-dideoxyinosine with 3-octadecyloxy-propane-1,2-diol by straightforward enzymatic regioselective synthesis in acetone.

  Biotechnology letters 20050101

• Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS.

  Lipids in health and disease 20050101

• Molecular strategies to inhibit HIV-1 replication.

  Retrovirology 20050101

• Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid.

  AIDS clinical care 20050101

• Maternal plasma viral load and neutralizing/enhancing antibodies in vertical transmission of HIV: a non-randomized prospective study.

  Virology journal 20050101

• Risk factors for hyperlactataemia in HIV-infected patients, Aquitaine Cohort, 1999--2003.

  Antiviral chemistry & chemotherapy 20050101

• Synergistic anti-viral effect of oxanosine and ddI against human immunodeficiency virus.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20050101

• Early virological failure with a combination of tenofovir, didanosine and efavirenz.

  Antiviral therapy 20050101

• Changes in mitochondrial RNA production in cells treated with nucleoside analogues.

  Antiviral therapy 20050101

• Abacavir, efavirenz, didanosine, with or without hydroxyurea, in HIV-infected adults failing initial nucleoside/protease inhibitor-containing regimens.

  BMC infectious diseases 20050101

• The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function.

  Antiviral therapy 20050101

• Mitochondrial toxicity of nucleoside analogues in primary human lymphocytes.

  Antiviral therapy 20050101

• In vitro combination studies of tenofovir and other nucleoside analogues with ribavirin against HIV-1.

  Antiviral therapy 20050101

• The influence of the M184V mutation in HIV-1 reverse transcriptase on the virological outcome of highly active antiretroviral therapy regimens with or without didanosine.

  Antiviral therapy 20050101

• Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients.

  Antiviral therapy 20050101

• Discrepancy between blood and cerebral didanosine effects in HIV patients: a magnetic resonance spectroscopy study.

  European neurology 20050101

• Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.

  BMC infectious diseases 20050101

• Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study.

  Antiviral therapy 20050101

• Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy.

  Antiviral therapy 20050101

• Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytes.

  Antiviral therapy 20050101

• Muscle and liver lactate metabolism in HAART-treated and naive HIV-infected patients: the MITOVIR study.

  Antiviral therapy 20050101

• Nucleoside reverse transcriptase inhibitors, mitochondrial DNA and AIDS therapy.

  Antiviral therapy 20050101

• The role of hepatitis C virus (HCV) in mitochondrial DNA damage in HIV/HCV-coinfected individuals.

  Antiviral therapy 20050101

• Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.

  Antiviral therapy 20050101

• The effect of long-term storage on measured plasma lactate concentrations and prospective lactate results from a multicenter trial of antiretroviral therapy.

  Clinical chemistry and laboratory medicine 20050101

• Mycobacterial immune reconstitution inflammatory syndrome in HIV-1 infection after antiretroviral therapy is associated with deregulated specific T-cell responses: beneficial effect of IL-2 and GM-CSF immunotherapy.

  Journal of immune based therapies and vaccines 20050101

• In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs.

  Antiviral chemistry & chemotherapy 20050101

• Homo and heterodimers of ddI, d4T and AZT: influence of (5'-5') thiolcabonate-carbamate linkage on anti-HIV activity.

  Nucleosides, nucleotides & nucleic acids 20050101

• Phosphoramidate derivatives of 2',5'-dideoxyadenosine as potential inhibitors of the EDHF phenomenon.

  Nucleosides, nucleotides & nucleic acids 20050101

• Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).

  HIV clinical trials 20050101

• Hepatic and renal safety profile of tenofovir in HIV-infected patients with hepatitis C, including patients on interferon plus ribavirin.

  HIV clinical trials 20050101

• Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.

  Antiviral therapy 20050101

• Sex differences in antiretroviral therapy-associated intolerance and adverse events.

  Drug safety 20050101

• Prevalence and evolution of drug resistance HIV-1 variants in Henan, China.

  Cell research 20050101

• [Treatment of chronic hepatitis C in patients with HIV infection].

  Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti 20050101

• In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis.

  Antiviral therapy 20050101

• [In vitro selection and phenotyping of HIV-1 mutants resistant to azidothymidine and didanosine].

  Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] 20050101

• Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naïve patients: the VESD study.

  HIV clinical trials 20050101

• Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review.

  Journal of the International AIDS Society 20050101

• Cytokine profiles in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy.

  Journal of the International AIDS Society 20050101

• Hypertriglyceridemia in antiretroviral therapy.

  Journal of the International AIDS Society 20050101

• Frequency of Drug-Resistant Variants of HIV-1 Coexistent With Wild-Type in Treatment-Naive Patients of India.

  Journal of the International AIDS Society 20050101

• Genetic barriers to resistance and impact on clinical response.

  Journal of the International AIDS Society 20050101

• A case-control study of HIV-associated pancreatic abnormalities during HAART era. Focus on emerging risk factors and specific management.

  European journal of medical research 20041222

• Upregulatory mechanisms compensate for mitochondrial DNA depletion in asymptomatic individuals receiving stavudine plus didanosine.

  Journal of acquired immune deficiency syndromes (1999) 20041215

• CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.

  AIDS (London, England) 20041203

• Nonnucleoside HIV-1 reverse transcriptase inhibitors; part 3. Synthesis and antiviral activity of 5-alkyl-2-[(aryl and alkyloxyl-carbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones.

  Bioorganic chemistry 20041201

• Randomized, controlled trial of therapy interruption in chronic HIV-1 infection.

  PLoS medicine 20041201

• Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.

  Antiviral therapy 20041201

• Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in antiretroviral-naive HIV patients in Campania, Italy.

  Journal of chemotherapy (Florence, Italy) 20041201

• Test and teach. Number Fifty-three. Diagnosis: Diabetes-related dyslipidaemia.

  Pathology 20041201

• CADA, a novel CD4-targeted HIV inhibitor, is synergistic with various anti-HIV drugs in vitro.

  AIDS (London, England) 20041105

• The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro.

  AIDS (London, England) 20041105

• Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients.

  AIDS (London, England) 20041105

• Broad specificity of human phosphoglycerate kinase for antiviral nucleoside analogs.

  Biochemical pharmacology 20041101

• Hyperlactatemia in human immunodeficiency virus-uninfected infants who are exposed to antiretrovirals.

  Pediatrics 20041101

• Magnitude and duration of elevated gastric pH in patients infected with human immunodeficiency virus after administration of chewable, dispersible, buffered didanosine tablets.

  Pharmacotherapy 20041101

• Warning on two specific 3-drug regimens: Viread + Didanosine + either Sustiva or Viramune.

  AIDS treatment news 20041029

• Acute onset of pancreatitis with concomitant use of tenofovir and didanosine.

  The Annals of pharmacotherapy 20041001

• Resveratrol glucuronides as the metabolites of resveratrol in humans: characterization, synthesis, and anti-HIV activity.

  Journal of pharmaceutical sciences 20041001

• Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals.

  Journal of virological methods 20041001

• Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.

  Prescrire international 20041001

• Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.

  PLoS medicine 20041001

• Effects of zidovudine, stavudine and beta-aminoisobutyric acid on lipid homeostasis in mice: possible role in human fat wasting.

  Antiviral therapy 20041001

• Prevalence of toxoplasma encephalitis in AIDS patients treated with Didanosine hospitalised in a French infectious service.

  Current HIV research 20041001

• Binding of anti-HIV drugs to human serum albumin.

  IUBMB life 20041001

• Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy.

  AIDS (London, England) 20040903

• Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.

  Journal of acquired immune deficiency syndromes (1999) 20040901

• New nucleoside/nucleotide backbone options: a review of recent studies.

  Journal of acquired immune deficiency syndromes (1999) 20040901

• Effectiveness and tolerability of a once-daily amprenavir/ritonavir-containing highly active antiretroviral therapy regimen in antiretroviral-naïve patients at risk for nonadherence: 48-week results after 24 weeks of directly observed therapy.

  HIV medicine 20040901

• Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.

  AIDS research and human retroviruses 20040901

• Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance.

  AIDS (London, England) 20040820

• Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound.

  The Journal of infectious diseases 20040815

• A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting.

  Journal of acquired immune deficiency syndromes (1999) 20040801

• Distinct patterns of natural selection in the reverse transcriptase gene of HIV-1 in the presence and absence of antiretroviral therapy.

  Virology 20040801

• Activation of c-Jun N-terminal kinase mediates gp120IIIB- and nucleoside analogue-induced sensory neuron toxicity.

  Experimental neurology 20040801

• Unusual muscle disease in HIV infected patients.

  Sexually transmitted infections 20040801

• Fatal lactic acidosis associated with coadministration of didanosine and tenofovir disoproxil fumarate.

  Pharmacotherapy 20040801

• Gynaecomastia in HIV-infected men on highly active antiretroviral therapy: association with efavirenz and didanosine treatment.

  Antiviral therapy 20040801

• Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial.

  JAMA 20040714

• HIV hollow fiber SCID model for antiviral therapy comparison with SCID/hu model.

  Antiviral research 20040701

• Frequency of Tk and Hprt lymphocyte mutants and bone marrow micronuclei in mice treated neonatally with zidovudine and didanosine.

  Mutagenesis 20040701

• Unexpected drug interactions and adverse events with antiretroviral drugs.

  Lancet (London, England) 20040701

• Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.

  Lancet (London, England) 20040701

• Prognostic factors in lactic acidosis syndrome caused by nucleoside reverse transcriptase inhibitors: report of eight cases and review of the literature.

  AIDS patient care and STDs 20040701

• Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients.

  Antiviral chemistry & chemotherapy 20040701

• 5-Alkyl-2-[(aryl and alkyloxylcarbonylmethyl)thio]-6-(1-naphthylmethyl) pyrimidin-4(3H)-ones as an unique HIV reverse transcriptase inhibitors of S-DABO series.

  Bioorganic & medicinal chemistry letters 20040621

• Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea.

  AIDS (London, England) 20040618

• Gynecomastia and potent antiretroviral therapy.

  AIDS (London, England) 20040618

• A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions.

  The Journal of biological chemistry 20040611

• Antiviral drugs in current clinical use.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20040601

• In vivo examination of hydroxyurea and the novel ribonucleotide reductase inhibitors trimidox and didox in combination with the reverse transcriptase inhibitor abacavir: suppression of retrovirus-induced immunodeficiency disease.

  Antiviral research 20040601

• A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection.

  The Journal of infectious diseases 20040601

• Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.

  Journal of acquired immune deficiency syndromes (1999) 20040601

• Brain virus burden and indoleamine-2,3-dioxygenase expression during lentiviral infection of rhesus monkey are concomitantly lowered by 6-chloro-2',3'-dideoxyguanosine.

  The European journal of neuroscience 20040601

• Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.

  Antiviral therapy 20040601

• Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.

  Antiviral therapy 20040601

• Tolerance of didanosine as enteric-coated capsules versus buffered tablets.

  AIDS patient care and STDs 20040601

• Novel polysulfated galactose-derivatized dendrimers as binding antagonists of human immunodeficiency virus type 1 infection.

  Antimicrobial agents and chemotherapy 20040501

• [Confirmed NRTI remains an important therapy option. Didanosine effective despite multiple resistance to NRTIs].

  MMW Fortschritte der Medizin 20040426

• [Progress in the treatment of hepatitis B and C co-infection in HIV patients].

  MMW Fortschritte der Medizin 20040426

• [Lactic acidosis in HIV-patients--diagnosis and treatment].

  MMW Fortschritte der Medizin 20040426

• Interval-censored survival time data: confidence intervals for the non-parametric survivor function.

  Statistics in medicine 20040415

• Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494).

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040415

• Nucleoside analogues and mitochondrial toxicity.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20040415

• Which nucleoside and nucleotide backbone combinations select for the K65R mutation in HIV-1 reverse transcriptase.

  AIDS (London, England) 20040409

• Tenofovir-related nephrotoxicity in HIV-infected patients.

  AIDS (London, England) 20040409

• Fatal lactic acidosis associated with highly active antiretroviral therapy in patients with advanced human immunodeficiency virus infection in Taiwan.

  International journal of STD & AIDS 20040401

• Didanosine-associated toxicity: a predictable complication of therapy with tenofovir and didanosine?

  Journal of acquired immune deficiency syndromes (1999) 20040401

• Pseudo-likelihood estimation for a marginal multivariate survival model.

  Statistics in medicine 20040330

• Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients.

  AIDS (London, England) 20040326

• 'African medicine' and Reye's syndrome.

  Lancet (London, England) 20040313

• A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).

  The Journal of antimicrobial chemotherapy 20040301

• A survival method to estimate the time to occurrence of mutations: an application to thymidine analogue mutations in HIV-1-infected patients.

  The Journal of infectious diseases 20040301

• Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial).

  HIV medicine 20040301

• Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases.

  Journal of acquired immune deficiency syndromes (1999) 20040301

• Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.

  AIDS (London, England) 20040220

• Didanosine, interferon-alfa, and ribavirin.

  AIDS (London, England) 20040220

• The role of civil society in protecting public health over commercial interests: lessons from Thailand.

  Lancet (London, England) 20040214

• Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype.

  The Journal of antimicrobial chemotherapy 20040201

• Newer treatments for HIV in children.

  Current opinion in pediatrics 20040201

• Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine.

  Hepatology (Baltimore, Md.) 20040201

• Determination of carrier-mediated transport of 2',3'-dideoxypurine nucleosides in the rat ileum using a bidirectional perfusion technique.

  Pharmaceutical research 20040201

• Glycine 154 of the equilibrative nucleoside transporter, hENT1, is important for nucleoside transport and for conferring sensitivity to the inhibitors nitrobenzylthioinosine, dipyridamole, and dilazep.

  Biochemical pharmacology 20040201

• Mitochondrial effects of antiretroviral therapies in asymptomatic patients.

  Antiviral therapy 20040201

• Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis.

  Antiviral therapy 20040201

• Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.

  Antiviral therapy 20040201

• High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin.

  Antiviral therapy 20040201

• Structures of human purine nucleoside phosphorylase complexed with inosine and ddI.

  Biochemical and biophysical research communications 20040123

• Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients.

  AIDS (London, England) 20040123

• Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome.

  AIDS (London, England) 20040123

• Liquid chromatographic-tandem mass spectrometric assay for the simultaneous determination of didanosine and stavudine in human plasma, bronchoalveolar lavage fluid, alveolar cells, peripheral blood mononuclear cells, seminal plasma, cerebrospinal fluid and tonsil tissue.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20040105

• Transport of physiological nucleosides and anti-viral and anti-neoplastic nucleoside drugs by recombinant Escherichia coli nucleoside-H(+) cotransporter (NupC) produced in Xenopus laevis oocytes.

  Molecular membrane biology 20040101

• Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy.

  Expert opinion on investigational drugs 20040101

• Novel mechanism of enhanced nociception in a model of AIDS therapy-induced painful peripheral neuropathy in the rat.

  Pain 20040101

• Greater and more rapid depletion of mitochondrial DNA in blood of patients treated with dual (zidovudine+didanosine or zidovudine+zalcitabine) vs. single (zidovudine) nucleoside reverse transcriptase inhibitors.

  HIV medicine 20040101

• Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors.

  The Pediatric infectious disease journal 20040101

• Genetic damage detected in CD-1 mouse pups exposed perinatally to 3'-azido-3'-deoxythymidine and dideoxyinosine via maternal dosing, nursing, and direct gavage.

  Environmental and molecular mutagenesis 20040101

• T-cell receptor excision circles (TREC) in SHIV 89.6p and SIVmac251 models of HIV-1 infection.

  DNA and cell biology 20040101

• EU issues warning about HAART regimen.

  AIDS patient care and STDs 20040101

• A rapid and sensitive method for simultaneous determination of lamivudine and zidovudine in human serum by on-line solid-phase extraction coupled to liquid chromatography/tandem mass spectrometry detection.

  Rapid communications in mass spectrometry : RCM 20040101

• K65R, TAMs and tenofovir.

  AIDS reviews 20040101

• Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics.

  Clinical pharmacokinetics 20040101

• Initiation of antiretroviral therapy: implications of recent findings.

  Topics in HIV medicine : a publication of the International AIDS Society, USA 20040101

• Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.

  BMC infectious diseases 20040101

• Chemical genomics in yeast.

  Genome biology 20040101

• Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools.

  Clinical pharmacokinetics 20040101

• Genetic damage detected in CD-1 mouse pups exposed perinatally to 3'-azido-3'-deoxythymidine or dideoxyinosine via maternal dosing, nursing, and direct gavage: II. Effects of the individual agents compared to combination treatment.

  Environmental and molecular mutagenesis 20040101

• Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors).

  Psychosomatics 20040101

• Spectrum of clinical disease in a series of 135 hospitalised HIV-infected patients from north India.

  BMC infectious diseases 20040101

• Pharmacokinetics of antiretrovirals in pregnant women.

  Clinical pharmacokinetics 20040101

• The unmasking of Pneumocystis jiroveci pneumonia during reversal of immunosuppression: case reports and literature review.

  BMC infectious diseases 20040101

• Efficacy and safety of abacavir plus lamivudine versus didanosine plus stavudine when combined with a protease inhibitor, a nonnucleoside reverse transcriptase inhibitor, or both in HIV-1 positive antiretroviral-naive persons.

  HIV clinical trials 20040101

• [Lipodystrophy in HIV infected children].

  Medycyna wieku rozwojowego 20040101

• Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase.

  Biochemistry 20031223

• Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20031215

• Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.

  The New England journal of medicine 20031211

• Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

  The New England journal of medicine 20031211

• HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use.

  AIDS (London, England) 20031205

• Didanosine-ribavirin combination: synergistic combination in vitro, but high potential risk of toxicity in vivo.

  AIDS (London, England) 20031205

• Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.

  Journal of the National Medical Association 20031201

• Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.

  Antiviral therapy 20031201

• The continuing evolution of HIV therapy.

  The AIDS reader 20031201

• French investigators warn of LPV/TDF/ddI interaction.

  IAPAC monthly 20031201

• Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis.

  AIDS (London, England) 20031121

• Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Didanosine intensification in NRTI-experienced patients.

  AIDS clinical care 20031101

• High rate of virologic failure with once-daily ddI/3TC/TDF.

  IAPAC monthly 20031101

• [Coinfection with hepatitis C virus and HIV].

  Nederlands tijdschrift voor geneeskunde 20031018

• Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial.

  AIDS (London, England) 20031017

• Hydroxyurea transport across the blood-brain and blood-cerebrospinal fluid barriers of the guinea-pig.

  Journal of neurochemistry 20031001

• Tenofovir disoproxil fumarate.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20031001

• Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.

  The Journal of infectious diseases 20031001

• Matched case-control study to evaluate risk factors for hyperlactataemia in HIV patients on antiretroviral therapy.

  HIV medicine 20031001

• Fatal lactic acidosis during antiretroviral therapy.

  Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies 20031001

• Incorporating prior beliefs about selection bias into the analysis of randomized trials with missing outcomes.

  Biostatistics (Oxford, England) 20031001

• Once-daily therapy: less is more.

  International journal of STD & AIDS 20031001

• The power of simplicity.

  International journal of STD & AIDS 20031001

• Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells.

  Antiviral therapy 20031001

• Evaluation of a didanosin-containing regimen including genotypic resistance testing: an open-label, multicenter study.

  European journal of medical research 20030929

• Low efficacy and high frequency of adverse events in a randomized trial of the triple nucleoside regimen abacavir, stavudine and didanosine.

  AIDS (London, England) 20030926

• Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.

  AIDS (London, England) 20030905

• Effect of transport inhibitors and additional anti-HIV drugs on the movement of lamivudine (3TC) across the guinea pig brain barriers.

  The Journal of pharmacology and experimental therapeutics 20030901

• Characterization of pentamidine excretion in the isolated perfused rat kidney.

  The Journal of antimicrobial chemotherapy 20030901

• Effect of tenofovir on didanosine absorption in patients with HIV.

  The Annals of pharmacotherapy 20030901

• Pancreatitis with didanosine and tenofovir disoproxil fumarate [corrected].

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030901

• Contraindicated antiretroviral drug combinations.

  New Jersey medicine : the journal of the Medical Society of New Jersey 20030901

• Efficacy and durability of nevirapine in antiretroviral drug näive patients.

  Journal of acquired immune deficiency syndromes (1999) 20030901

• Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy in HIV/AIDS patients.

  Antiviral chemistry & chemotherapy 20030901

• Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients.

  The Journal of infectious diseases 20030815

• Translesion replication in cisplatin-treated xeroderma pigmentosum variant cells is also caffeine-sensitive: features of the error-prone DNA polymerase(s) involved in UV-mutagenesis.

  DNA repair 20030812

• Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment.

  The Journal of infection 20030801

• Quantitation of blood lymphocyte mitochondrial DNA for the monitoring of antiretroviral drug-induced mitochondrial DNA depletion.

  Journal of acquired immune deficiency syndromes (1999) 20030801

• Incidence of liver toxicity in hiv-infected patients receiving isolated dual nucleoside analogue antitretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20030801

• Functional expression and characterization of a sodium-dependent nucleoside transporter hCNT2 cloned from human duodenum.

  Biochemical and biophysical research communications 20030801

• Lactic acidosis in HIV infected patients: a systematic review of published cases.

  Sexually transmitted infections 20030801

• A strategy for liquid chromatography/tandem mass spectrometric assays of intracellular drugs: application to the validation of the triphosphorylated anabolite of antiretrovirals in peripheral blood mononuclear cells.

  Journal of mass spectrometry : JMS 20030801

• [A short-term trial of Didanosine, stavudine, and nevirapine combination therapy for human immunodeficiency virus infection].

  Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University 20030801

• Feeding risk cut for HIV-infected women.

  Lancet (London, England) 20030726

• Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated patients.

  The Journal of infectious diseases 20030715

• Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial.

  Annals of internal medicine 20030715

• Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030705

• Effects of didanosine formulations on the pharmacokinetics of amprenavir.

  Pharmacotherapy 20030701

• Fatal lactic acidosis and mimicking Guillain-Barré syndrome in an adolescent with human immunodeficiency virus infection.

  The Pediatric infectious disease journal 20030701

• Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy.

  The AIDS reader 20030701

• Editorial comment: drug-drug interactions, hepatitis C, and mitochondrial toxicity.

  The AIDS reader 20030701

• Gastrointestinal side effects of drugs.

  Expert opinion on drug safety 20030701

• Semiparametric regression analysis of longitudinal data with informative drop-outs.

  Biostatistics (Oxford, England) 20030701

• Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.

  AIDS (London, England) 20030701

• Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance.

  The Journal of infectious diseases 20030615

• Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens.

  The Journal of infectious diseases 20030615

• Tenofovir disoproxil fumarate.

  The Annals of pharmacotherapy 20030601

• Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells.

  Pharmacotherapy 20030601

• Tenofovir poses risk with didanosine.

  AIDS patient care and STDs 20030601

• Comparison of nine resistance interpretation systems for HIV-1 genotyping.

  Antiviral therapy 20030601

• Polyphenotypic expression of mitochondrial toxicity caused by nucleoside reverse transcriptase inhibitors.

  Antiviral therapy 20030601

• Pathways for the emergence of multi-dideoxynucleoside-resistant HIV-1 variants.

  AIDS (London, England) 20030523

• Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030515

• A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.

  AIDS (London, England) 20030502

• Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus.

  AIDS (London, England) 20030502

• Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal.

  AIDS (London, England) 20030502

• Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients.

  AIDS (London, England) 20030502

• APHS can act synergically with clinically available HIV-1 reverse transcriptase and protease inhibitors and is active against several drug-resistant HIV-1 strains in vitro.

  The Journal of antimicrobial chemotherapy 20030501

• Once-a-day highly active antiretroviral therapy: a systematic review.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030501

• A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation.

  Journal of virology 20030501

• Site-specific differences in the action of NRTI drugs on adipose tissue incubated in vitro with lymphoid cells, and their interaction with dietary lipids.

  Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 20030501

• Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.

  International journal of STD & AIDS 20030501

• [Observational study on the efficacy of the application of two classical regimens of triple antiretroviral therapy].

  Anales de medicina interna (Madrid, Spain : 1984) 20030501

• Update on mitochondrial toxicity: where are we now?

  Journal of HIV therapy 20030501

• [Viral hepatitis B/C and HIV. Therapy of double infections].

  MMW Fortschritte der Medizin 20030428

• Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20030415

• Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication.

  Antimicrobial agents and chemotherapy 20030401

• Effects of hypokalemia and hypomagnesemia on zidovudine (AZT) and didanosine (ddI) nephrotoxicity in rats.

  Clinical nephrology 20030401

• Determination of didanosine in human serum by on-line solid-phase extraction coupled to high-performance liquid chromatography with electrospray ionization tandem mass spectrometric detection: application to a bioequivalence study.

  Journal of mass spectrometry : JMS 20030401

• HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.

  Antiviral therapy 20030401

• K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.

  Antiviral therapy 20030401

• Acute hepatic failure and lactate acidosis associated with antiretroviral treatment for HIV.

  Wiener klinische Wochenschrift 20030227

• Toward the development of a virus-cell-based assay for the discovery of novel compounds against human immunodeficiency virus type 1.

  Antimicrobial agents and chemotherapy 20030201

• Mitochondrial disruption and apoptosis in lymphocytes of an HIV infected patient affected by lactic acidosis after treatment with highly active antiretroviral therapy.

  Journal of clinical pathology 20030201

• Mechanisms by which 2',3'-dideoxyinosine (ddI) crosses the guinea-pig CNS barriers; relevance to HIV therapy.

  Journal of neurochemistry 20030201

• Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children.

  Journal of clinical pharmacology 20030201

• Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors.

  Virology 20030201

• Predictive factors and selection of thymidine analogue mutations by nucleoside reverse transcriptase inhibitors according to initial regimen received.

  Antiviral therapy 20030201

• [Antiretrovirals].

  Nihon rinsho. Japanese journal of clinical medicine 20030201

• AIDS-associated diarrhea and wasting in Northeast Brazil is associated with subtherapeutic plasma levels of antiretroviral medications and with both bovine and human subtypes of Cryptosporidium parvum.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20030201

• Case report: nucleoside analogue-induced lactic acidosis in the third trimester of pregnancy.

  AIDS (London, England) 20030124

• Symptomatic hyperlactatemia in an HIV-positive patient: a case report and discussion.

  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20030121

• Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy.

  The Journal of infectious diseases 20030101

• Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.

  Journal of acquired immune deficiency syndromes (1999) 20030101

• Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.

  Pharmacotherapy 20030101

• Prevalence, risk factors and outcome of hyperlactataemia in HIV-infected patients.

  HIV medicine 20030101

• Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms.

  HIV medicine 20030101

• Pharmacokinetics of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.

  The Pediatric infectious disease journal 20030101

• Delivery of didanosine from enteric-coated, sustained-release bioadhesive formulation.

  Drug delivery 20030101

• Double 'd' drug danger.

  The AIDS reader 20030101

• First-line therapy and mitochondrial damage: different nucleosides, different findings.

  HIV clinical trials 20030101

• Multiple relapses of human cytomegalovirus retinitis during HAART in an AIDS patient with reconstitution of CD4+ T cell count in the absence of HCMV-specific CD4+ T cell response.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20030101

• [Severe lactic acidosis in HIV-infected patients treated with nucleosidic reverse transcriptase analogs: a report of 9 cases].

  La Revue de medecine interne 20030101

• In vitro activity of potential anti-poxvirus agents.

  Antiviral research 20030101

• Severe cutaneous reactions associated with the use of human immunodeficiency virus medications.

  Acta dermato-venereologica 20030101

• New questions about an old combination--ddI + d4T.

  Project Inform perspective 20030101

• Prevalence of genotypic HIV-1 drug resistance in Thailand, 2002.

  Annals of clinical microbiology and antimicrobials 20030101

• Lopinavir/ritonavir: a review of its use in the management of HIV infection.

  Drugs 20030101

• Tenofovir drug interactions: ddI and d4T.

  TreatmentUpdate 20030101

• Self-reported health-related quality of life in persons with HIV infection: results from a multi-site interview project.

  Health and quality of life outcomes 20030101

• HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).

  Antiviral chemistry & chemotherapy 20030101

• Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.

  Drug safety 20030101

• Determination of stavudine in human serum by on-line solid-phase extraction coupled to high-performance liquid chromatography with electrospray ionization tandem mass spectrometry: application to a bioequivalence study.

  Rapid communications in mass spectrometry : RCM 20030101

• Atazanavir.

  Drugs 20030101

• Recommendations for postexposure prophylaxis of operating room personnel and patients exposed to bloodborne diseases.

  Journal of long-term effects of medical implants 20030101

• [Decrease of HIV-1 replicative capacity after serial passage in MT-4 cells under conditions of the combined antiretroviral therapy].

  Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic] 20030101

• Synthesis of new homo and heterodimers of 2',3'-dideoxyinosine (ddI) using ester linkages.

  Nucleosides, nucleotides & nucleic acids 20030101

• In vitro study of resistance-associated genotypic mutations to nucleoside analogs.

  Nucleosides, nucleotides & nucleic acids 20030101

• Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection.

  The Cochrane database of systematic reviews 20030101

• Insulin-like growth factor-1 protects ischemic murine myocardium from ischemia/reperfusion associated injury.

  Critical care (London, England) 20030101

• Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy.

  HIV clinical trials 20030101

• [Development of approaches to enhancing of patient adherence to antivirus therapy in the treatment of human immunodeficiency virus infection].

  Terapevticheskii arkhiv 20030101

• Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Checking up on ddI and tenofovir in people with HIV/AIDS.

  TreatmentUpdate 20030101

• Multiple-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in HIV-Infected Patients.

  Clinical drug investigation 20030101

• Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.

  Journal of acquired immune deficiency syndromes (1999) 20021215

• Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.

  AIDS (London, England) 20021206

• Persistence of earlier HIV-1 drug resistance mutations at new treatment failure.

  Journal of medical virology 20021201

• Macrophage protection by addition of glutathione (GSH)-loaded erythrocytes to AZT and DDI in a murine AIDS model.

  Antiviral research 20021201

• Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir.

  Journal of acquired immune deficiency syndromes (1999) 20021201

• Single-dose pharmacokinetics of enteric-coated didanosine in HIV-infected children.

  Antiviral therapy 20021201

• Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine.

  Antiviral therapy 20021201

• New warning for ddI.

  AIDS patient care and STDs 20021201

• Thailand: successful challenge to invalid patent claim on antiretrovirals.

  Canadian HIV/AIDS policy & law review 20021201

• Intensification and stimulation therapy for human immunodeficiency virus type 1 reservoirs in infected persons receiving virally suppressive highly active antiretroviral therapy.

  The Journal of infectious diseases 20021115

• Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors.

  AIDS (London, England) 20021108

• The boosting of didanosine by allopurinol permits a halving of the didanosine dosage.

  AIDS (London, England) 20021108

• Determinations of zidovudine/didanosine/nevirapine and zidovudine/didanosine/ritonavir in human serum by micellar electrokinetic chromatography.

  Journal of pharmaceutical and biomedical analysis 20021107

• New anti-HIV agents and targets.

  Medicinal research reviews 20021101

• New saponins from the starfish Certonardoa semiregularis.

  Journal of natural products 20021101

• Can HIV infection be treated successfully with a once-daily regimen?

  The AIDS reader 20021101

• Repeated cycles of alternate administration of fludarabine and Zidovudine plus Didanosine inhibits murine AIDS and reduces proviral DNA content in lymph nodes to undetectable levels.

  Virology 20021025

• Thailand court forces reversal of drug firm antiretroviral patent.

  Lancet (London, England) 20021019

• Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.

  The Journal of infectious diseases 20021001

• Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.

  Journal of acquired immune deficiency syndromes (1999) 20021001

• [Cytomegalovirus retinitis after highly active antiretroviral therapy: a case report].

  Archivos de la Sociedad Espanola de Oftalmologia 20020901

• Pharmacokinetics and gamma scintigraphy evaluation of two enteric coated formulations of didanosine in healthy volunteers.

  British journal of clinical pharmacology 20020901

• The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA.

  Journal of acquired immune deficiency syndromes (1999) 20020901

• ['Normal' compliance is not enough. HIV therapy loses effectiveness].

  MMW Fortschritte der Medizin 20020822

• [Pharmacological and clinical properties of didanosine (VIDEX), a nucleoside reverse transcriptase inhibitor].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20020801

• Anti-HIV agents. Tenofovir and Videx (ddi) EC--some caution required.

  TreatmentUpdate 20020801

• Eudragit RS-PM and Ethocel 100 Premium: influence over the behavior of didanosine inert matrix system.

  Farmaco (Societa chimica italiana : 1989) 20020801

• New developments in anti-HIV chemotherapy.

  Biochimica et biophysica acta 20020718

• 3'-Azido-2',3'-dideoxythymidine induced deficiency of thymidine kinases 1, 2 and deoxycytidine kinase in H9 T-lymphoid cells.

  Biochemical pharmacology 20020715

• Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors.

  AIDS (London, England) 20020705

• An ancient prevertebrate Na+-nucleoside cotransporter (hfCNT) from the Pacific hagfish (Eptatretus stouti).

  American journal of physiology. Cell physiology 20020701

• ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.

  Antimicrobial agents and chemotherapy 20020701

• Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir.

  Antiviral research 20020701

• Bioequivalence of two formulations of didanosine, encapsulated enteric-coated beads and buffered tablet, in healthy volunteers and HIV-infected subjects.

  Journal of clinical pharmacology 20020701

• Exposure to dideoxynucleosides is reflected in lowered mitochondrial DNA in subcutaneous fat.

  Journal of acquired immune deficiency syndromes (1999) 20020701

• Comparison of virtual phenotype and HIV-SEQ program (Stanford) interpretation for predicting drug resistance of HIV strains.

  HIV medicine 20020701

• Genotypic and phenotypic analysis of a novel 15-base insertion occurring between codons 69 and 70 of HIV type 1 reverse transcriptase.

  AIDS research and human retroviruses 20020701

• Diadenosine pentaphosphate vasodilates the forearm vascular bed: inhibition by theophylline and augmentation by dipyridamole.

  Clinical pharmacology and therapeutics 20020601

• [Mononucleosis syndrome with viro-immunologic parameters similar to those of a primary HIV-1 infection after interruption of highly effective anti-retroviral treatment].

  Anales de medicina interna (Madrid, Spain : 1984) 20020601

• A rapid phenotypic assay for detecting multiple nucleoside analogue reverse transcriptase inhibitor-resistant HIV-1 in plasma.

  Antiviral therapy 20020601

• L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine.

  Antioxidants & redox signaling 20020601

• Significant differences between plasma HIV-1 RNA assays in HIV-1 subtype E infected patients treated with antiretroviral therapy.

  Asian Pacific journal of allergy and immunology 20020601

• HIV-1 subtype C reverse transcriptase sequences from drug-naive pregnant women in South Africa.

  AIDS research and human retroviruses 20020520

• Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1.

  Lancet (London, England) 20020511

• Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats.

  Drug metabolism and disposition: the biological fate of chemicals 20020501

• Impact of missing data due to selective dropouts in cohort studies and clinical trials.

  Epidemiology (Cambridge, Mass.) 20020501

• Concurrent analysis of nucleoside reverse transcriptase inhibitors in a pool of endogenous nucleosides by short-end injection-capillary electrochromatography on a beta-cyclodextrin-bonded stationary phase.

  Electrophoresis 20020501

• Impact of highly active antiretroviral therapy on cognitive processing in HIV infection: cross-sectional and longitudinal studies of event-related potentials.

  AIDS research and human retroviruses 20020501

• Didanosine extended-release matrix tablets: optimization of formulation variables using statistical experimental design.

  International journal of pharmaceutics 20020426

• Antisense epidermal growth factor receptor RNA transfection in human glioblastoma cells down-regulates telomerase activity and telomere length.

  British journal of cancer 20020422

• Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors.

  Journal of acquired immune deficiency syndromes (1999) 20020415

• Dose-escalating study of the safety and pharmacokinetics of nelfinavir in HIV-exposed neonates.

  Journal of acquired immune deficiency syndromes (1999) 20020415

• Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.

  Antiviral research 20020401

• Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir.

  Antimicrobial agents and chemotherapy 20020401

• Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection.

  Journal of acquired immune deficiency syndromes (1999) 20020401

• Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.

  The Journal of infectious diseases 20020401

• Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads.

  Journal of clinical pharmacology 20020401

• The dangers of inferring treatment effects from observational data: a case study in HIV infection.

  Controlled clinical trials 20020401

• Body composition changes in protease inhibitor-naive HIV-infected patients treated with two nucleoside reverse transcriptase inhibitors.

  HIV medicine 20020401

• Gateways to Clinical Trials.

  Methods and findings in experimental and clinical pharmacology 20020401

• [Treatment of chronic hepatitis C in patients coinfected with HIV: tolerability, drug interactions, therapeutic indications].

  Gastroenterologie clinique et biologique 20020401

• Development of sustained release matrix tablets of didanosine containing methacrylic and ethylcellulose polymers.

  International journal of pharmaceutics 20020302

• Prevalence of the mutational pattern E44D/A and/or V118I in the reverse transcriptase (RT) gene of HIV-1 in relation to treatment with nucleoside analogue RT inhibitors.

  Journal of medical virology 20020301

• Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020301

• Acanthosis nigricans: a new manifestation of insulin resistance in patients receiving treatment with protease inhibitors.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20020301

• Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors.

  Antimicrobial agents and chemotherapy 20020301

• Novel use of a guanosine prodrug approach to convert 2',3'-didehydro-2',3'-dideoxyguanosine into a viable antiviral agent.

  Antimicrobial agents and chemotherapy 20020301

• Efavirenz-induced skin eruption and successful desensitization.

  The Annals of pharmacotherapy 20020301

• Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole.

  Biopharmaceutics & drug disposition 20020301

• Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy.

  Antiviral therapy 20020301

• Efficacy of low-dose interferon with antiretroviral therapy in Kaposi's sarcoma: a randomized phase II AIDS clinical trials group study.

  Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20020301

• Prevalence of HIV-1 polymerase gene mutations in pre-treated patients in Thailand.

  The Southeast Asian journal of tropical medicine and public health 20020301

• T69D/N pol mutation, human immunodeficiency virus type 1 RNA levels, and syncytium-inducing phenotype are associated with CD4 cell depletion during didanosine therapy.

  The Journal of infectious diseases 20020215

• S-acyl-2-thioethyl (SATE) pronucleotides are potent inhibitors of HIV-1 replication in T-lymphoid cells cross-resistant to deoxycytidine and thymidine analogs.

  Antiviral research 20020201

• A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.

  Journal of virology 20020201

• Investigation of the mechanism of enhancement of central nervous system delivery of 2'-beta-fluoro-2',3'-dideoxyinosine via a blood-brain barrier adenosine deaminase-activated prodrug.

  Drug metabolism and disposition: the biological fate of chemicals 20020201

• Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries.

  Journal of acquired immune deficiency syndromes (1999) 20020201

• Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication.

  Sexually transmitted infections 20020201

• Reiter's syndrome associated with the Acquired Immunodeficiency Syndrome: a case report.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20020201

• Lymphocytes proliferate in blood and lymph nodes following interleukin-2 therapy in addition to highly active antiretroviral therapy.

  AIDS (London, England) 20020125

• Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.

  AIDS research and human retroviruses 20020120

• Human infection with Cryptosporidium felis: case report and literature review.

  Emerging infectious diseases 20020101

• Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails.

  Journal of acquired immune deficiency syndromes (1999) 20020101

• Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen.

  Journal of acquired immune deficiency syndromes (1999) 20020101

• Necrotizing cutaneous lesions complicating treatment with pegylated-interferon alfa in an HIV-infected patient.

  European journal of dermatology : EJD 20020101

• Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter.

  HIV clinical trials 20020101

• Viral and immunologic follow up of 4 to 9 years of AIDS treatments by quadruple combinations of virostatics including integrase inhibitors applied in short sequences differing by drug rotation.

  Acta pharmacologica Sinica 20020101

• Improved method for the simultaneous determination of d4T, 3TC and ddl intracellular phosphorylated anabolites in human peripheral-blood mononuclear cells using high-performance liquid chromatography/tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20020101

• Response to two consecutive protease inhibitor combination therapy regimens in a cohort of HIV-1-infected children.

  Scandinavian journal of infectious diseases 20020101

• Control of HIV during a structured treatment interruption in chronically infected individuals with vigorous T cell responses.

  HIV clinical trials 20020101

• Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.

  HIV clinical trials 20020101

• SENC (Spanish efavirenz vs. nevirapine comparison) trial: a randomized, open-label study in HIV-infected naive individuals.

  HIV clinical trials 20020101

• Food-drug interactions.

  Drugs 20020101

• Molecular analysis of mutations at the HPRT and TK loci of human lymphoblastoid cells after combined treatments with 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosinedagger.

  Environmental and molecular mutagenesis 20020101

• Clinical implications of CNS penetration of antiretroviral drugs.

  CNS drugs 20020101

• Oral and dental care and treatment protocols for the management of HIV-infected patients.

  Oral diseases 20020101

• The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.

  HIV clinical trials 20020101

• Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV.

  HIV clinical trials 20020101

• Antiretroviral pharmacokinetics in the paediatric population: a review.

  Clinical pharmacokinetics 20020101

• Determination of lamivudine/didanosine/nevirapine in human serum using capillary zone electrophoresis.

  Journal of capillary electrophoresis and microchip technology 20020101

• Update on didanosine.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20020101

• Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.

  AIDS (London, England) 20011207

• Highly active antiretroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy.

  AIDS (London, England) 20011207

• Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine.

  AIDS (London, England) 20011207

• Analysis of intracellular didanosine triphosphate at sub-ppb level using LC-MS/MS.

  Journal of pharmaceutical and biomedical analysis 20011201

• Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20011201

• Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20011201

• Metastatic small cell carcinoma presenting as acute hepatic failure.

  The American journal of gastroenterology 20011201

• Toxic interaction of didanosine and acetaminophen leading to severe hepatitis and pancreatitis: a case report and review of the literature.

  The American journal of gastroenterology 20011201

• Emerging role of riboflavin in the treatment of nucleoside analogue-induced type B lactic acidosis.

  AIDS patient care and STDs 20011201

• HIV-1 reverse transcriptase mutations found in a drug-experienced patient confer reduced susceptibility to multiple nucleoside reverse transcriptase inhibitors.

  Antiviral therapy 20011201

• Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz.

  Antiviral therapy 20011201

• [Therapeutic aspects of HIV/AIDS infected patients and evaluation of therapeutic protocols].

  Acta pharmaceutica Hungarica 20011201

• Drugs for HIV infection.

  The Medical letter on drugs and therapeutics 20011126

• Anti-human immunodeficiency virus drugs are ineffective against Pneumocystis carinii in vitro and in vivo.

  The Journal of infectious diseases 20011115

• Impaired absorption of rifabutin by concomitant administration of didanosine.

  AIDS (London, England) 20011109

• New developments in anti-HIV chemotherapy.

  Current medicinal chemistry 20011101

• Differential kinetics of transport of 2',3'-dideoxyinosine and adenosine via concentrative Na+ nucleoside transporter CNT2 cloned from rat blood-brain barrier.

  The Journal of pharmacology and experimental therapeutics 20011101

• [Acute myocardial infarct in HIV-positive patients in treatment with protease inhibitors].

  Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology 20011101

• Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study.

  Lancet (London, England) 20011020

• Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).

  AIDS research and human retroviruses 20011010

• Tolerability of enteric-coated didanosine capsules compared with didanosine tablets in adults with HIV infection.

  Journal of acquired immune deficiency syndromes (1999) 20011001

• HIV-1 induction-maintenance at the lymph node level: the 'Apollo-97' Study.

  Journal of acquired immune deficiency syndromes (1999) 20011001

• Potential adverse effects of structured therapeutic interruptions on the pool of HIV-infected cells.

  Journal of acquired immune deficiency syndromes (1999) 20011001

• Treatment of human immunodeficiency virus-related lymphoma.

  Seminars in hematology 20011001

• New formulation of ddI approved in Canada--Videx EC.

  TreatmentUpdate 20011001

• Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.

  The Journal of infectious diseases 20010915

• Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.

  The Journal of biological chemistry 20010914

• Direct analysis of mitochondrial toxicity of antiretroviral drugs.

  AIDS (London, England) 20010907

• Immunological and virological effects of long term IL-2 therapy in HIV-1-infected patients.

  AIDS (London, England) 20010907

• Mismatched double-stranded RNA (polyI-polyC(12)U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro.

  Antiviral research 20010901

• Liver failure after long-term nucleoside antiretroviral therapy.

  Lancet (London, England) 20010901

• Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine.

  AIDS research and human retroviruses 20010901

• Amphotericin B-induced seizures in a patient with AIDS.

  The Annals of pharmacotherapy 20010901

• Differential effects of nucleoside analogs on oxidative phosphorylation in human pancreatic cells.

  Digestive diseases and sciences 20010901

• Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study.

  Journal of acquired immune deficiency syndromes (1999) 20010901

• Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999.

  European journal of clinical pharmacology 20010901

• Simultaneous quantitation of nucleoside HIV-1 reverse transcriptase inhibitors by short-end injection capillary electrochromatography on a beta-cyclodextrin-bonded silica stationary phase.

  Journal of chromatography. A 20010824

• Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.

  The Journal of infectious diseases 20010815

• Antiviral drugs: current state of the art.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20010801

• Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.

  AIDS (London, England) 20010727

• Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.

  AIDS (London, England) 20010706

• Gynaecomastia in a male patient during stavudine and didanosine treatment for HIV infection.

  International journal of STD & AIDS 20010701

• Antiretroviral-induced hepatic steatosis and lactic acidosis: case report and review of the literature.

  The American surgeon 20010701

• A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.

  Journal of acquired immune deficiency syndromes (1999) 20010701

• [Immunologic response to antiretroviral treatment with combined stavudine, didanosine and nevirapine].

  Presse medicale (Paris, France : 1983) 20010701

• Orofacial effects of antiretroviral therapies.

  Oral diseases 20010701

• Evidence for prolonged clinical benefit from initial combination antiretroviral therapy: Delta extended follow-up.

  HIV medicine 20010701

• Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis.

  MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports 20010629

• Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).

  The Journal of infectious diseases 20010615

• High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.

  AIDS (London, England) 20010615

• [Symptomatic hyperlactemia in patients infected with the human immunodeficiency virus treated with nucleoside analogs].

  Medicina clinica 20010609

• Mitochondrial toxic effects and ribavirin.

  Lancet (London, England) 20010602

• Mitochondrial toxic effects and ribavirin.

  Lancet (London, England) 20010602

• A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.

  Journal of acquired immune deficiency syndromes (1999) 20010601

• Full recovery from severe dilated cardiomyopathy in an HIV-infected patient.

  The AIDS reader 20010601

• Nucleoside analogue-induced fatal lactic acidosis in two HIV-infected patients in Singapore.

  Singapore medical journal 20010601

• Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia.

  Lancet (London, England) 20010505

• HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health.

  AIDS (London, England) 20010504

• 4'-Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro.

  Antimicrobial agents and chemotherapy 20010501

• Choosing which nuke to use first.

  The AIDS reader 20010501

• [HIV-HBV coinfection and the liver].

  Gastroenterologie clinique et biologique 20010501

• Three-drug combinations of emivirine and nucleoside reverse transcriptase inhibitors in vitro: long-term culture of HIV-1-infected cells and breakthrough viruses.

  Antiviral chemistry & chemotherapy 20010501

• A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection.

  Journal of acquired immune deficiency syndromes (1999) 20010415

• High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.

  Journal of acquired immune deficiency syndromes (1999) 20010415

• Determination of serum levels of thirteen human immunodeficiency virus-suppressing drugs by high-performance liquid chromatography.

  Journal of chromatography. A 20010413

• Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine.

  AIDS (London, England) 20010413

• [Didanosine as a capsule. A reliable drug in a new dosage form].

  MMW Fortschritte der Medizin 20010402

• Resolution of chronic parvovirus b19-induced anemia, by use of highly active antiretroviral therapy, in a patient with acquired immunodeficiency syndrome.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20010401

• Amino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profiles.

  Journal of virology 20010401

• Gynecomastia associated with highly active antiretroviral therapy.

  The Annals of pharmacotherapy 20010401

• ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1.

  Controlled clinical trials 20010401

• An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.

  Controlled clinical trials 20010401

• Vertical HIV-1 transmission: prophylaxis and paediatric follow-up.

  Placenta 20010401

• Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1.

  Molecular therapy : the journal of the American Society of Gene Therapy 20010401

• [A rare etiology of hepatic steatosis associated with lactic acidosis: the toxicity of antiviral nucleoside analogues].

  Annales de pathologie 20010401

• Peripheral neuropathy during stavudine-didanosine antiretroviral therapy.

  HIV medicine 20010401

• Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype.

  AIDS (London, England) 20010330

• Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.

  AIDS (London, England) 20010330

• Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection.

  AIDS (London, England) 20010309

• Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.

  The Journal of infectious diseases 20010301

• Peripheral neuropathy and antiretroviral drugs.

  Journal of the peripheral nervous system : JPNS 20010301

• Virological response in multidrug-experienced HIV-1-infected subjects failing highly active combination regimens after shifting from lamivudine to didanosine.

  Antiviral therapy 20010301

• Differential susceptibility of retroviruses to nucleoside analogues.

  Antiviral chemistry & chemotherapy 20010301

• Dynamics of seminal plasma HIV-1 decline after antiretroviral treatment.

  AIDS (London, England) 20010216

• Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection.

  AIDS research and human retroviruses 20010210

• The potential place of chloroquine in the treatment of HIV-1-infected patients.

  Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20010201

• Antiretroviral treatments used among adults with HIV infection in Europe.

  AIDS care 20010201

• Lack of an effect of azithromycin on the disposition of zidovudine and dideoxyinosine in HIV-infected patients.

  Journal of clinical pharmacology 20010201

• Genetic risks of antiviral nucleoside analogues--a survey.

  Antiviral research 20010201

• Oral sustained-release bioadhesive tablet formulation of didanosine.

  Drug development and industrial pharmacy 20010201

• Bristol-Myers warns of AIDS drugs' use.

  The AIDS reader 20010201

• Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.

  Journal of medicinal chemistry 20010201

• Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection.

  AIDS (London, England) 20010126

• Drug Points: pancreatitis associated with hydroxyurea in combination with didanosine.

  BMJ (Clinical research ed.) 20010113

• d4T plus ddI: warning for pregnant women.

  AIDS treatment news 20010112

• Fluorometric determination of 2'-beta-fluoro-2',3'-dideoxyadenosine 5'-triphosphate, the active metabolite of a new anti-human immunodeficiency virus drug, in human lymphocytes.

  Analytical biochemistry 20010101

• Pilot study of a combination of highly active antiretroviral therapy and cytokines to induce HIV-1 remission.

  Journal of acquired immune deficiency syndromes (1999) 20010101

• Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians.

  Pharmacotherapy 20010101

• [Bilateral hip necrosis, corticoids, and human immunodeficiency virus protease inhibitors].

  Enfermedades infecciosas y microbiologia clinica 20010101

• An algorithm for mapping positively selected members of quasispecies-type viruses.

  BMC bioinformatics 20010101

• New version of didanosine.

  AIDS patient care and STDs 20010101

• Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem?

  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20010101

• Delavirdine: clinical pharmacokinetics and drug interactions.

  Clinical pharmacokinetics 20010101

• Myelopathy in a previously asymptomatic HIV-1-infected patient.

  Infection 20010101

• New developments in anti-HIV chemotherapy.

  Farmaco (Societa chimica italiana : 1989) 20010101

• Warning for pregnant women on HIV therapy.

  FDA consumer 20010101

• Transport of antiviral 3'-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes.

  Molecular membrane biology 20010101

• Eruptive cheilitis: a new adverse effect in reactive HIV-positive patients subjected to high activity antiretroviral therapy (HAART). Presentation of six clinical cases.

  Medicina oral : organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia y Medicina Bucal 20010101

• HIV-1 multi-dideoxynucleoside resistance mutation (Q151M): prevalence, associated resistance mutations and response to antiretroviral salvage treatment.

  Microbios 20010101

• Clinical and laboratory signs of mitochondrial dysfunction secondary to nucleoside analogue antiretroviral therapy are reversible.

  Scandinavian journal of infectious diseases 20010101

• Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples.

  Nucleosides, nucleotides & nucleic acids 20010101

• Analysis of anti-HIV nucleoside inhibitors by capillary electrophoresis-electrospray ionization mass spectrometry.

  Nucleosides, nucleotides & nucleic acids 20010101

• Differential human immunodeficiency virus-suppressive activity of reverse transcription inhibitors in resting and activated peripheral blood lymphocytes: implications for therapy.

  Journal of human virology 20010101

• DABOs as candidates to prevent mucosal HIV transmission.

  Antiviral chemistry & chemotherapy 20010101

• Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.

  Antiviral therapy 20010101

• Continuing HIV therapy in the ICU.

  Critical care (London, England) 20010101

• Prevalence and genetic heterogeneity of the reverse transcriptase T69S-S-X insertion in pretreated HIV-infected patients.

  Intervirology 20010101

• Caution issued for HIV combination therapy with Zerit and Videx in pregnant women.

  HIV clinician 20010101

• Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem?

  International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 20010101

• [Drug combination therapy for children infected with HIV/AIDS--own experience].

  Przeglad epidemiologiczny 20010101

• Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.

  Acta virologica 20010101

• Side effects. FDA issues warning about d4T and ddI during pregnancy.

  TreatmentUpdate 20010101

• Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins.

  Biological & pharmaceutical bulletin 20001201

• Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol.

  Journal of acquired immune deficiency syndromes (1999) 20001101

• Long-term hydroxyurea in combination with didanosine and stavudine for the treatment of HIV-1 infection. Swiss HIV Cohort Study.

  AIDS (London, England) 20000929

• Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.

  Antimicrobial agents and chemotherapy 20000801

• Didanosine-induced hepatitis.

  The American journal of gastroenterology 20000801

• In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.

  Antimicrobial agents and chemotherapy 20000701

• Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].

  Antiviral chemistry & chemotherapy 20000701

• Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5'-(4'-amino-1',2'-oxath iole-2',2'-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.

  AIDS research and human retroviruses 20000610

• Selection and characterization of human immunodeficiency virus type 1 variants resistant to the (+) and (-) enantiomers of 2'-deoxy-3'-oxa-4'-thio-5-fluorocytidine.

  Antimicrobial agents and chemotherapy 20000501

• Syntheses of oxanosine and carbocyclic oxanosine derivatives as anti-HIV agents.

  The Journal of antibiotics 20000301

• Incidence of neuropathy in HIV-infected patients on monotherapy versus those on combination therapy with didanosine, stavudine and hydroxyurea.

  AIDS (London, England) 20000218

• Excess peripheral neuropathy in patients treated with hydroxyurea plus didanosine and stavudine for HIV infection.

  AIDS (London, England) 20000218

• Temporal development of 2',3'-dideoxyinosine (ddI)-induced peripheral myelinopathy.

  Neurotoxicology and teratology 20000101

• Synthesis and anti-HIV evaluation of 2',3'-dideoxy imidazo- and nu-triazolo[4,5-d]pyridazine nucleosides.

  Bioorganic & medicinal chemistry 19991101

• Hydroxyurea reduces the 50% inhibitory concentration of didanosine in HIV-infected cells.

  AIDS (London, England) 19991022

• In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues.

  Antimicrobial agents and chemotherapy 19991001

• A novel genotype encoding a single amino acid insertion and five other substitutions between residues 64 and 74 of the HIV-1 reverse transcriptase confers high-level cross-resistance to nucleoside reverse transcriptase inhibitors. Abacavir CNA2007 International Study Group.

  Journal of acquired immune deficiency syndromes (1999) 19991001

• Safety and antiretroviral effects of combined didanosine and stavudine therapy in HIV-infected individuals with CD4 counts of 200 to 500 cells/mm3.

  Journal of acquired immune deficiency syndromes (1999) 19990901

• Once-daily administration of didanosine in combination with stavudine in antiretroviral-naive patients. The STADI Group.

  Journal of acquired immune deficiency syndromes (1999) 19990901

• Hydroxyurea-induced neurotoxicity in HIV disease.

  AIDS (London, England) 19990820

• Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity.

  Journal of acquired immune deficiency syndromes (1999) 19990815

• Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.

  Clinical therapeutics 19990701

• In vitro anti-human immunodeficiency virus activities of Z- and E-methylenecyclopropane nucleoside analogues and their phosphoro-L-alaninate diesters.

  Antimicrobial agents and chemotherapy 19990601

• cycloSal-Pronucleotides of 2',3'-dideoxyadenosine and 2', 3'-dideoxy-2',3'-didehydroadenosine: synthesis and antiviral evaluation of a highly efficient nucleotide delivery system.

  Journal of medicinal chemistry 19990506

• Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.

  Antiviral chemistry & chemotherapy 19990301

• Effect of nucleoside analogs and non-nucleoside inhibitors of HIV-1 reverse transcriptase on cell-free virions.

  Archives of virology 19990101

• Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.

  Antimicrobial agents and chemotherapy 19981101

• Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries.

  AIDS (London, England) 19981022

• Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent.

  AIDS (London, England) 19980709

• Metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitro.

  Antimicrobial agents and chemotherapy 19980701

• 3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants.

  Journal of virology 19980601

• S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1.

  Antimicrobial agents and chemotherapy 19980601

• Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance.

  The Journal of infectious diseases 19980501

• Tri-N-Boc-tetraazamacrocycle-nucleoside conjugates: synthesis and anti-HIV activities.

  Nucleosides & nucleotides 19980501

• Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).

  Biochemical pharmacology 19980301

• Deafness caused by didanosine.

  European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 19980301

• A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.

  AIDS research and human retroviruses 19980210

• Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.

  AIDS research and human retroviruses 19980120

• Mutations in the human immunodeficiency virus type 1 reverse transcriptase gene observed in stavudine and didanosine strains obtained by in vitro passages.

  Research in virology 19980101

• Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1.

  Journal of virology 19971101

• Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses.

  Journal of virology 19971101

• Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance.

  AIDS research and human retroviruses 19971101

• Zidovudine-resistant human immunodeficiency virus type 1 strains subcultured in the presence of both lamivudine and quinoxaline HBY 097 retain marked sensitivity to HBY 097 but not to lamivudine.

  The Journal of infectious diseases 19971101

• Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses.

  Antiviral research 19971101

• Sequence and drug susceptibility of subtype C reverse transcriptase from human immunodeficiency virus type 1 seroconverters in Zimbabwe.

  Journal of virology 19970701

• Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus.

  Antimicrobial agents and chemotherapy 19970701

• Effects of 2',3'-dideoxyinosine on Toxoplasma gondii cysts in mice.

  Antimicrobial agents and chemotherapy 19970701

• Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes.

  Journal of leukocyte biology 19970701

• Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus.

  FEBS letters 19970630

• In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-beta-Fluoro-2',3'-dideoxyadenosine.

  Antimicrobial agents and chemotherapy 19970601

• Metabolites of the antipsychotic agent clozapine inhibit the replication of human immunodeficiency virus type 1.

  Schizophrenia research 19970503

• 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity.

  Antimicrobial agents and chemotherapy 19970501

• Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89.

  Antimicrobial agents and chemotherapy 19970501

• Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years.

  Antimicrobial agents and chemotherapy 19970401

• Effects of RP 55778, a tumor necrosis factor alpha synthesis inhibitor, on antiviral activity of dideoxynucleosides.

  Antimicrobial agents and chemotherapy 19970401

• A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates.

  The Journal of infectious diseases 19970301

• Lecithinized superoxide dismutase: an inhibitor of human immunodeficiency virus replication.

  AIDS research and human retroviruses 19970301

• Irreversible ototoxicity associated with zalcitabine.

  International journal of STD & AIDS 19970301

• Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine.

  Antiviral research 19970301

• Dideoxyinosine-induced pancreatitis in human immunodeficiency virus-infected children.

  Pediatric radiology 19970201

• Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues.

  AIDS (London, England) 19970201

• Inhibition of sandfly fever Sicilian virus (Phlebovirus) replication in vitro by antiviral compounds.

  Research in virology 19970101

• In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA).

  Antiviral research 19961001

• Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro.

  Antimicrobial agents and chemotherapy 19960901

• Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.

  Biochemical and biophysical research communications 19960814

• Highly favorable antiviral activity and resistance profile of the novel thiocarboxanilide pentenyloxy ether derivatives UC-781 and UC-82 as inhibitors of human immunodeficiency virus type 1 replication.

  Molecular pharmacology 19960801

• Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication.

  Antimicrobial agents and chemotherapy 19960601

• Antiviral activities of nucleotide heterodimers against human immunodeficiency virus type 1 in vitro.

  Antiviral research 19960601

• Synergistic inhibition of human immunodeficiency virus isolates (including 3'-azido-3'-deoxythymidine-resistant isolates) by foscarnet in combination with 2',3'-dideoxyinosine or 2',3'-dideoxycytidine.

  Antimicrobial agents and chemotherapy 19960501

• New arylpyrido-diazepine and -thiodiazepine derivatives are potent and highly selective HIV-1 inhibitors targeted at the reverse transcriptase.

  Antiviral research 19960501

• Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus.

  Biochemical pharmacology 19960322

• Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1.

  Antiviral research 19960301

• Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.

  Journal of virology 19960201

• New drug developments for opportunistic infections in immunosuppressed patients: Pneumocystis carinii.

  Journal of medicinal chemistry 19951124

• Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells.

  Antimicrobial agents and chemotherapy 19951101

• Potent inhibition of human immunodeficiency virus by MDL 101028, a novel sulphonic acid polymer.

  Antiviral research 19951001

• Characterisation of foscarnet-resistant strains of human immunodeficiency virus type 1.

  Virology 19950910

• Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2',3'-dideoxynucleoside activities against replication of human immunodeficiency virus.

  Proceedings of the National Academy of Sciences of the United States of America 19950829

• K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine.

  Antimicrobial agents and chemotherapy 19950801

• Enhancement by hydroxyurea of the anti-human immunodeficiency virus type 1 potency of 2'-beta-fluoro-2',3'-dideoxyadenosine in peripheral blood mononuclear cells.

  Biochemical pharmacology 19950717

• The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.

  Antimicrobial agents and chemotherapy 19950601

• Synthesis, antiviral activity and enzymatic phosphorylation of 9-phosphonopentenyl derivatives of guanine.

  Antiviral research 19950601

• A simple and rapid method for preliminary evaluation of in vivo efficacy of anti-HIV compounds in mice.

  Antiviral research 19950501

• Novel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolates.

  Antimicrobial agents and chemotherapy 19950501

• Siamycins I and II, new anti-HIV peptides: I. Fermentation, isolation, biological activity and initial characterization.

  The Journal of antibiotics 19950501

• Lipophilic, acid-stable, adenosine deaminase-activated anti-HIV prodrugs for central nervous system delivery. 2. 6-Halo and 6-alkoxy prodrugs of 2'-beta-fluoro-2',3'-dideoxyinosine.

  Journal of medicinal chemistry 19950331

• Synthesis and antiviral activity of 3'-fluorocarbocyclic oxetanocin A.

  Chemical & pharmaceutical bulletin 19950101

• Inhibition of human immunodeficiency virus type 1 replication in cytokine-stimulated monocytes/macrophages by combination therapy.

  The Journal of infectious diseases 19941201

• New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs.

  Antimicrobial agents and chemotherapy 19941201

• Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations.

  AIDS research and human retroviruses 19941201

• Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes.

  Proceedings of the National Academy of Sciences of the United States of America 19941108

• Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication.

  Science (New York, N.Y.) 19941104

• Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy.

  The Journal of infectious diseases 19941101

• Synthesis and evaluation of the anti-HIV activity of aza and deaza analogues of isoddA and their phosphates as prodrugs.

  Journal of medicinal chemistry 19941014

• Characterization of the anti-HIV-1 activity of 3,4-dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs), new non-nucleoside reverse transcriptase inhibitors.

  The new microbiologica 19941001

• Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines.

  Antimicrobial agents and chemotherapy 19941001

• Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides.

  Molecular pharmacology 19941001

• Cutaneous vasculitis associated with didanosine.

  Lancet (London, England) 19940903

• Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.

  Annals of internal medicine 19940815

• Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3'-azido-2',3'-dideoxythymidine.

  Biochemical pharmacology 19940705

• 5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile.

  Antimicrobial agents and chemotherapy 19940701

• Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors.

  Antimicrobial agents and chemotherapy 19940601

• Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture.

  Antimicrobial agents and chemotherapy 19940601

• In vitro susceptibility of clinical isolates of HIV-1 to XM323, a non-peptidyl HIV protease inhibitor.

  AIDS (London, England) 19940601

• [Range of neuromuscular involvement in 47 patients infected with the human immunodeficiency virus].

  Schweizerische medizinische Wochenschrift 19940514

• Effect of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine on establishment of human immunodeficiency virus type 1 infection in cultured CD8+ lymphocytes.

  Antimicrobial agents and chemotherapy 19940501

• Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy.

  Journal of internal medicine 19940401

• Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.

  Antimicrobial agents and chemotherapy 19940201

• Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase.

  Antimicrobial agents and chemotherapy 19940201

• Anti-HIV activity of dideoxynucleosides, foscarnet and fusidic acid is potentiated by human leukocyte interferon in blood-derived macrophages.

  Chemotherapy 19940101

• Anti-angiogenesis agent DS-4152 is a potent and selective inhibitor of HIV-1 replication in vitro.

  AIDS (London, England) 19940101

• Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs.

  Journal of virology 19931201

• High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.

  Antimicrobial agents and chemotherapy 19931001

• Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus.

  Virology 19931001

• Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-1-specific [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro- 5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)]-beta-D-pentofurano syl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors.

  Proceedings of the National Academy of Sciences of the United States of America 19930801

• pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.

  Antimicrobial agents and chemotherapy 19930701

• Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.

  Proceedings of the National Academy of Sciences of the United States of America 19930615

• Synthesis and antiviral activity of adenosine deaminase-resistant oxetanocin A derivatives: 2-halogeno-oxetanocin A.

  The Journal of antibiotics 19930601

• The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.

  Antimicrobial agents and chemotherapy 19930601

• U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.

  Antimicrobial agents and chemotherapy 19930501

• In vitro anti-human immunodeficiency virus activity of 2',3'-dideoxynucleosides and their effect on clonal growth of hemopoietic cells from human bone marrow.

  Arzneimittel-Forschung 19930501

• Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.

  Antimicrobial agents and chemotherapy 19930401

• The use and toxicity of didanosine (ddI) in HIV antibody-positive individuals intolerant to zidovudine (AZT).

  The Quarterly journal of medicine 19930301

• Didanosine: long-term follow-up of patients in a phase 1 study.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 19930201

• Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5'-(4'-amino-1',2'- oxathiole-2',2'-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues.

  Molecular pharmacology 19930101

• A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).

  Molecular pharmacology 19930101

• HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase.

  Virology 19930101

• Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.

  Antimicrobial agents and chemotherapy 19930101

• Dideoxyinosine-associated nephrotoxicity.

  AIDS (London, England) 19930101

• Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.

  Journal of virology 19921201

• 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors.

  Antimicrobial agents and chemotherapy 19921201

• Didanosine therapy in patients intolerant of or failing zidovudine therapy.

  The Annals of pharmacotherapy 19921101

• Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia.

  Antimicrobial agents and chemotherapy 19920901

• Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.

  Antimicrobial agents and chemotherapy 19920901

• Characterization of oxyphenarsine as a potential antiviral agent for AIDS.

  AIDS research and human retroviruses 19920901

• 4-oxatetradecanoic acid is fungicidal for Cryptococcus neoformans and inhibits replication of human immunodeficiency virus I.

  The Journal of biological chemistry 19920825

• Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication.

  Antiviral research 19920701

• (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.

  Antimicrobial agents and chemotherapy 19920401

• In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase.

  Molecular pharmacology 19920301

• Substrate specificity of human deoxycytidine kinase toward antiviral 2',3'-dideoxynucleoside analogs.

  Biochemical pharmacology 19920122

• Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine.

  Antimicrobial agents and chemotherapy 19920101

• Extended follow-up of peripheral neuropathy in patients with AIDS and AIDS-related complex treated with dideoxyinosine.

  Journal of acquired immune deficiency syndromes 19920101

• Generation of nucleoside-resistant variants of HIV-1 by in vitro selection in the presence of AZT or DDI but no by combinations.

  Leukemia 19920101

• In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.

  Journal of virology 19920101

• Phase I study of 2'-3'-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine.

  The American journal of medicine 19911101

• Synthesis and anti-HIV-1 activity of 4,5,6,7-tetrahydro-5-methylimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-on e (TIBO) derivatives. 2.

  Journal of medicinal chemistry 19911101

• Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.

  The Journal of infectious diseases 19911001

• Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

  Science (New York, N.Y.) 19910927

• Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors.

  Journal of virology 19910901

• Fulminant hepatic failure associated with 2',3'-dideoxyinosine (ddI).

  Annals of internal medicine 19910815

• 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) and 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) markedly potentiate the inhibitory effect of 2',3'-dideoxyinosine on human immunodeficiency virus in peripheral blood lymphocytes.

  Biochemical and biophysical research communications 19910731

• Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity.

  Molecular pharmacology 19910501

• Escherichia coli mediated biosynthesis and in vitro anti-HIV activity of lipophilic 6-halo-2',3'-dideoxypurine nucleosides.

  Journal of medicinal chemistry 19910501

• Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization.

  Proceedings of the National Academy of Sciences of the United States of America 19910415

• The inhibitory activity of a peptide derivative against the growth of simian immunodeficiency virus in C8166 cells.

  Biochemical and biophysical research communications 19910415

• Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity.

  Journal of medicinal chemistry 19910401

• Optic neuritis associated with dideoxyinosine.

  Lancet (London, England) 19910309

• Alpha-(1-3)- and alpha-(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro.

  Antimicrobial agents and chemotherapy 19910301

• Anti-human immunodeficiency virus synergism by zidovudine (3'-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells.

  Antimicrobial agents and chemotherapy 19910201

• Dideoxyinosine-associated hypokalaemia.

  Lancet (London, England) 19910119

• Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine.

  Journal of acquired immune deficiency syndromes 19910101

• Lipophilic halogenated congeners of 2',3'-dideoxypurine nucleosides active against human immunodeficiency virus in vitro.

  Proceedings of the National Academy of Sciences of the United States of America 19901201

• Ability of anti-HIV agents to inhibit HIV replication in monocyte/macrophages or U937 monocytoid cells under conditions of enhancement by GM-CSF or anti-HIV antibody.

  AIDS research and human retroviruses 19900801

• Synthesis and structure-activity relationships of 6-substituted 2',3'-dideoxypurine nucleosides as potential anti-human immunodeficiency virus agents.

  Journal of medicinal chemistry 19900601

• Activities of 3'-azido-3'-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1.

  Antimicrobial agents and chemotherapy 19900601

• Susceptibility to nucleoside analogues of zidovudine-resistant isolates of human immunodeficiency virus.

  The American journal of medicine 19900521

• American Society for Biochemistry and Molecular Biology, the American Association of Immunologists, joint meeting. New Orleans, Louisiana, June 4-7, 1990. Abstracts 1-3659, TU1-TU35, indexes.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 19900426

• Acid-stable 2'-fluoro purine dideoxynucleosides as active agents against HIV.

  Journal of medicinal chemistry 19900301

• In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors.

  Antimicrobial agents and chemotherapy 19900101

• The National Cancer Institute phase I study of 2',3'-dideoxyinosine administration in adults with AIDS or AIDS-related complex: analysis of activity and toxicity profiles.

  Reviews of infectious diseases 19900101

• Phase I study of 2',3'-dideoxyinosine: experience with 19 patients at New York University Medical Center.

  Reviews of infectious diseases 19900101

• 2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex.

  Reviews of infectious diseases 19900101

• Treatment of AIDS and AIDS-related complex with 2',3'-dideoxyinosine given once daily.

  Reviews of infectious diseases 19900101

• Potentiating effect of ribavirin on the in vitro and in vivo antiretrovirus activities of 2',3'-dideoxyinosine and 2',3'-dideoxy-2,6-diaminopurine riboside.

  Journal of acquired immune deficiency syndromes 19900101

• Overview of phase I trials of 2',3'-dideoxyinosine (ddI) conducted on adult patients.

  Reviews of infectious diseases 19900101

• Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GM-CSF) potentiates viral production yet enhances the antiviral effect mediated by 3'-azido-2'3'-dideoxythymidine (AZT) and other dideoxynucleoside congeners of thymidine.

  The Journal of experimental medicine 19890301

• Nucleotide dimers suppress HIV expression in vitro.

  AIDS research and human retroviruses 19881201

• Comparative activity of 2',3'-saturated and unsaturated pyrimidine and purine nucleosides against human immunodeficiency virus type 1 in peripheral blood mononuclear cells.

  Biochemical pharmacology 19881001

• Adenallene and cytallene: acyclic-nucleoside analogues that inhibit replication and cytopathic effect of human immunodeficiency virus in vitro.

  Proceedings of the National Academy of Sciences of the United States of America 19880801

• Dideoxynucleosides are less inhibitory in vitro against human immunodeficiency virus type 2 (HIV-2) than against HIV-1.

  Antimicrobial agents and chemotherapy 19871201

• Lysosomotropic agents. 7. Broad-spectrum antifungal activity of lysosomotropic detergents.

  Journal of medicinal chemistry 19870801

• Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

  Proceedings of the National Academy of Sciences of the United States of America 19860301